Biopharmaceutical Industry
Speakers List

Cost and Value of Medicines
About the Speakers List

The Biopharmaceutical Industry Speakers List contains names of executives at the Pharmaceutical Research and Manufacturers of America (PhRMA) and its member companies available to participate in events and panel discussions on the cost and value of prescription medicines. A photo, biography and contact information is available for each speaker. There is no fee associated with any speaking engagement.

Parties interested in securing a speaker should contact these individuals directly to discuss their participation. PhRMA and its member companies will attempt to accommodate all requests, but cannot guarantee participation.

For questions or more information, please contact the PhRMA Newsroom at newsroom@phrma.org or call 202-835-3460.
Available Speakers

**PhRMA**

**JEFFREY BOND**  
Senior Vice President, Advocacy  
Washington, D.C.

**JENNIFER BRYANT**  
Senior Vice President, Policy and Research  
Washington, D.C.

**RANDY BURKHOLDER**  
Vice President, Policy and Research  
Washington, D.C.

**WILLIAM “BILL” CHIN, M.D.**  
Chief Medical Officer and Executive Vice President, Science and Regulatory Affairs  
Washington, D.C.

**JOSEPHINE “JOSIE” C. MARTIN**  
Executive Vice President, Public Affairs  
Washington, D.C.

**LORI M. REILLY, J.D.**  
Executive Vice President, Policy and Research  
Washington, D.C.

**JAMES “MIT” M. SPEARS, J.D.**  
General Counsel, Executive Vice President, Legal  
Washington, D.C.

**STEPHEN J. UBL**  
President and Chief Executive Officer  
Washington, D.C.

**MICHAEL YBARRA, M.D.**  
Senior Director, Alliance Development  
Washington, D.C.

**ROBERT ZIRKELBACH**  
Senior Vice President, Communications  
Washington, D.C.

**PhRMA Member Companies**

**AbbVie**

**LATIF AKINTADE, M.D., MBA**  
Vice President, Global Market Access  
North Chicago, Illinois

**SCOTT BRUN, M.D.**  
Vice President, Pharmaceutical Development  
North Chicago, Illinois

**JEFFREY R. STEWART**  
Vice President, U.S. Commercial Operations  
North Chicago, Illinois

**JAMES P. SULLIVAN, PH.D.**  
Vice President, Discovery  
North Chicago, Illinois
# PhRMA Member Companies

**Amgen Inc.**

RESHMA KEWALRAMANI, M.D. FASN  
Head, U.S. Medical Organization  
Vice President, Global Medical  
*Thousand Oaks, California*

MARK MORGAN  
Executive Director, U.S. Commercial Operations  
*Thousand Oaks, California*

JOSHUA J. OFMAN, M.D., MSHS  
Senior Vice President, Global Value, Access and Policy  
*Thousand Oaks, California*

MARTIN ZAGARI, M.D.  
Vice President, Global Health Economics  
*Thousand Oaks, California*

**Astrazeneca**

CHRISTINE BLOOMQUIST, J.D.  
Vice President, Federal Government Affairs and Policy  
*Washington, D.C.*

DAVE FREDRICKSON  
Vice President, Specialty Care  
*Gaithersburg, Maryland*

PAUL HUDSON  
President, U.S. and Executive Vice President, North America  
*Wilmington, Delaware*

**Bayer**

PHILIP BLAKE  
President, U.S. and Head of Americas Region, Pharmaceuticals  
*Whippany, New Jersey*

SHANNON CAMPBELL  
Vice President and General Manager, Oncology  
*Whippany, New Jersey*

HABIB DABLE  
President, U.S. Pharmaceuticals  
*Whippany, New Jersey*

KEVIN O’LEARY  
Vice President, Strategic Pricing and Reimbursement  
*Whippany, New Jersey*
PhRMA Member Companies

**Biogen Inc.**

DAVID MILLER, PH.D.  
Senior Vice President, Global Market Access  
Cambridge, Massachusetts

ALFRED SANDROCK, JR., M.D., PH.D.  
Executive Vice President, Neurology Discovery and Development Center, Neurodegeneration Therapeutic Area and Chief Medical Officer  
Cambridge, Massachusetts

KATHLEEN TREGONING  
Senior Vice President, Corporate Affairs  
Washington, D.C.

**Boehringer Ingelheim Pharmaceuticals, Inc.**

JAMES BAXTER, PHARM.D., PH.D.  
Senior Vice President, Development  
Ridgefield, Connecticut

PAUL FONTEYENE  
President and Chief Executive Officer  
Ridgefield, Connecticut

DAVID S. MEMEL, M.D., M.S., MBA  
Vice President, Health Economics and Outcomes Research  
Ridgefield, Connecticut

JOANNE PALMISANO, M.D., FACP  
Vice President, Regulatory Affairs  
Ridgefield, Connecticut

**Bristol-Myers Squibb Company**

CHRISTOPHER BOERNER, PH.D.  
President and Head, U.S. Commercial Operations  
Plainsboro, New Jersey

MURDO GORDON  
Senior Vice President and Head, Worldwide Markets  
Princeton, New Jersey

FOUAD NAMOUNI, M.D.  
Head, Medical  
Princeton, New Jersey

KEVIN TRAPP  
Head, Product, Portfolio and Access Strategy  
Princeton, New Jersey

**Celgene Corporation**

MARK ALLES  
President and Chief Operating Officer  
Summit, New Jersey

RICHARD BAGGER  
Executive Vice President, Corporate Affairs and Market Access  
Summit, New Jersey

JOEL BEETSCHE, PH.D.  
Vice President, Patient Advocacy  
Summit, New Jersey

BRIAN GILL  
Vice President, Corporate Communications  
Summit, New Jersey
PhRMA Member Companies

Eli Lilly and Company

ALEX AZAR
President, Lilly USA
Indianapolis, Indiana

ENRIQUE CONTERNO
Senior Vice President and President, Lilly Diabetes
Indianapolis, Indiana

NEWTON F. CRENSHAW
Vice President, Lilly Oncology, U.S. and Canada
Indianapolis, Indiana

SHERRY MARTIN, M.D.
Vice President, Clinical Development Operations, Diabetes
Indianapolis, Indiana

DAVE RICKS
Senior Vice President and President, Bio-Medicines
Indianapolis, Indiana

EMD Serono, Inc.

MICHAEL J. RUGGIERO
Vice President, U.S. Government Affairs and Policy
Washington, D.C.

GlaxoSmithKline plc

JACK BAILEY
President, U.S. Pharmaceuticals
Research Triangle Park, North Carolina

TANISHA CARINO, PH.D.
Vice President, U.S. Public Policy
Washington, D.C.

Caroline De Marco
Vice President, Regional Accounts
Philadelphia, Pennsylvania

Jamey Millar
Senior Vice President, Managed Markets and Government Affairs
Research Triangle Park, North Carolina

Horizon Pharma

Jeffrey D. Kent, M.D., FACG
Senior Vice President, Medical Affairs and Clinical Outcomes
Deerfield, Illinois

Jeffrey W. Sherman, M.D., FACP
Chief Medical Officer and Executive Vice President
Deerfield, Illinois

Janssen Pharmaceutical Companies of Johnson & Johnson

Anastasia G. Daifotis, M.D.
Chief Scientific Officer, Janssen Titusville, New Jersey

Elizabeth Fowler, Ph.D., J.D.
Vice President, Global Health Policy, Johnson & Johnson
Washington, D.C.

Blasine Penkowski
Chief Strategic Customer Officer, Janssen Titusville, New Jersey
PhRMA Member Companies

Mallinckrodt

MATTHEW HARBAUGH
Senior Vice President and Chief Financial Officer
St. Louis, Missouri

HUGH O’NEILL
Senior Vice President and President, Autoimmune and Rare Diseases
St. Louis, Missouri

STEVEN ROMANO, M.D.
Senior Vice President and Chief Scientific Officer
St. Louis, Missouri

Merck & Co., Inc.

PATRICK DAVISH
Associate Vice President, Global Market Access - Global Pricing
Upper Gwynedd, Pennsylvania

PATRICK MAGRI
Senior Vice President, Hospital and Specialty Business Unit
Upper Gwynedd, Pennsylvania

Novartis Pharmaceuticals Corporation

WILLIAM HINSHAW
Executive Vice President, U.S. Oncology
East Hanover, New Jersey

CHRISTI SHAW
U.S. Country Head, President
East Hanover, New Jersey

ROBERT SPURR
U.S. Country Head and Vice President, Patient Access and Health Policy
East Hanover, New Jersey

Novo Nordisk, Inc.

TODD HOBBS, M.D.
Vice President, Chief Medical Officer, North America
Plainsboro, New Jersey

CURT G. OLMANS
Corporate Vice President and General Counsel
Plainsboro, New Jersey

SEAN PHILLIPS
Vice President, Managed Markets
Plainsboro, New Jersey

Orexigen Therapeutics, Inc.

MICHAEL A. NARACHI
President and Chief Executive Officer
La Jolla, San Diego, California

Otsuka America Pharmaceutical, Inc.

JOHN BARDI
Vice President, Government Affairs
Rockville, Maryland

ROB LAVERTY
Vice President, Market Access
Princeton, New Jersey

BOB OLIVER
President & Chief Operating Officer
Princeton, New Jersey
PhRMA Member Companies

**Pfizer Inc.**

**KIRSTEN AXELSEN**  
Vice President, Global Policy  
New York, New York

**GENO GERMANO**  
Group President,  
Global Innovative Pharma Business  
New York, New York

**JUSTIN MCCARTHY, J.D.**  
Senior Vice President,  
Global Policy and International Affairs  
New York, New York

**Sanofi**

**PAUL CHEW, M.D.**  
Global Chief Medical Officer  
Bridgewater, New Jersey, and Paris, France

**SURESH KUMAR**  
Executive Vice President, External Affairs  
Paris, France

**DAVID MEEKER, M.D.**  
Executive Vice President and Head,  
Sanofi Genzyme  
Cambridge, Massachusetts

**JEZ MOULDING**  
U.S. Country Chair  
North America Region Head, Diabetes & Cardiovascular Business Unit  
Bridgewater, New Jersey

**GARY J. NABEL, M.D., PH.D.**  
Chief Scientific Officer,  
Global Research and Development  
Paris, France, and Bethesda, Maryland

**Takeda Pharmaceuticals USA, Inc.**

**ELIAS ZERHOUNI, M.D.**  
President, Global Research & Development  
Paris, France, and Bethesda, Maryland

**RICHARD “RICK” ASCROFT**  
Vice President, Managed Markets and Government Affairs  
Deerfield, Illinois

**RAMONA SEQUEIRA**  
President, U.S. Business Unit  
Deerfield, Illinois
Jeffrey Bond
PhRMA
Senior Vice President, State Advocacy
Washington, DC

With over 30 years’ experience in the pharmaceutical and health care industry, Jeff Bond has worked in corporate, commercial and trade association roles. As senior vice president, state advocacy, Jeff leads the Pharmaceutical Research and Manufacturers of America (PhRMA) state advocacy operations. At PhRMA, he is responsible for directing the association’s state lobbying and policy analysis activities in close coordination with senior executives from member companies. He is responsible for the development and execution of strategies consistent with member company public policy objectives.

Prior to joining PhRMA, Jeff served as vice president, state government affairs at Bristol-Myers Squibb. There, he led all company advocacy activity with state elected officials and key stakeholders. In his leadership role at Bristol-Myers Squibb, Jeff was a member of Patient Assistance Foundation Board of Directors, the Women’s Health Philanthropy Board and he served on the U.S. Pharmaceuticals Operating Committee.

Jeff’s career in the pharmaceutical business began when he joined the CIBA-Geigy Corporation as a sales representative for Geigy Pharmaceuticals. He was promoted through positions of increasing responsibility and was recognized with the company’s highest sales and marketing honor, the Circle of Excellence Award, four times. After joining CIBA’s government affairs department in 1987, Jeff represented the company’s legislative interests in a seven-state region. In 1993 he was appointed executive director of state government affairs where he supported the president of CIBA, who served as chairman of the PhRMA’s state government affairs key issue team.
Jennifer Bryant
PhRMA
Senior Vice President, Policy and Research
Washington, DC

Jenny Bryant serves as senior vice president, policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA), the national association representing the country’s leading pharmaceutical research and biotechnology companies.

At PhRMA, she oversees development of public policy related to Medicare, Medicaid and health care reform, as well analysis and policy development related to changes in the health care delivery system. She oversees a broad portfolio of economic and policy research, with a focus on better understanding how medicines are used and valued and the impact of appropriate medication use on health care costs.

Prior to joining PhRMA, Ms. Bryant was vice president at The Lewin Group, a national health care consulting firm. Previously, she held management positions at Blue Cross Blue Shield Association, Blue Cross Blue Shield of Florida, New York Hospital-Cornell Medical Center and the State of New York.

Ms. Bryant graduated magna cum laude from Harvard College and received her MBA from the Harvard Graduate School of Business Administration.
Randy Burkholder is vice president of policy and research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, the Center for Medicare & Medicaid Services’ technical expert panel on oncology and the federal coordinating council for comparative effectiveness research. He also is a former member of the board of directors of the personalized medicine coalition and serves on the steering committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.

Mr. Burkholder has over 20 years of experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Prior to joining PhRMA, Mr. Burkholder was associate vice president for public affairs at AdvaMed, the leading association of the medical device and diagnostics industries.
William “Bill” W. Chin, M.D. is the chief medical officer and executive vice president at the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. Dr. Chin leads the organization’s continuing efforts in science advocacy in the drug discovery and development ecosystem.

He was the executive dean for research, Bertarelli professor of translational medical science and professor of medicine at Harvard Medical School (HMS). In this role, Dr. Chin spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crossed departmental and institutional boundaries.

Chin is a Harvard-trained endocrinologist and longstanding faculty member. His impressive career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the HMS faculty. During his tenure as a faculty member in the department of medicine at Brigham and Women’s Hospital, he became chief of the genetics division and a Howard Hughes Medical Institute investigator, advancing to professor of medicine and obstetrics, gynecology and reproductive biology at HMS.

As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership.

Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for a decade, most recently as senior vice president for discovery research and clinical investigation. He received his A.B. (Chemistry; summa cum laude) from Columbia University and his M.D. from Harvard Medical School.

CONTACT INFORMATION
PhRMA Newsroom
Email: newsroom@phrma.org
Phone: 202-835-3460
Josephine “Josie” C. Martin is executive vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. She leads the organization’s communications and alliance development functions and serves as a key advisor to PhRMA’s president, management and board of directors.

Working at the intersection of public policy, health and business, Ms. Martin oversees PhRMA’s public affairs efforts to support an environment that fosters medical innovation, new drug discovery and access to life-saving medicines.

In a career spanning more than 20 years, Ms. Martin has established herself as a leading health care communications and public affairs expert. Prior to joining PhRMA, she served as senior vice president at Ketchum, where she built a widely respected public affairs health care practice and provided counsel to a wide range of blue chip corporate clients and several leading nonprofit organizations. Ms. Martin was also senior vice president of public affairs at GolinHarris, where she oversaw advocacy efforts for a wide array of health care clients, including America on the Move, Olympus, Dow Chemical Company, Kaiser Permanente, Boehringer Ingelheim, Robert Wood Johnson Foundation and drugstore.com, among others. Under her leadership, the American Legacy Foundation launched the largest public health cessation program in 40 years. She also developed the advocacy strategies for Olympus in Washington, D.C., with a focus on colorectal cancer awareness, medical device regulation and business opportunities within the 2009 stimulus program.

Ms. Martin has also held leadership positions with the Federation of American Hospitals, the Health Insurance Association of America and the American Red Cross. In addition, she served as communications director to the Senate Finance Committee and press secretary to Senator John Chafee (R-RI).
Lori M. Reilly, J.D.
PhRMA
Executive Vice President, Policy and Research
Washington, DC

Lori M. Reilly is executive vice president for policy and research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Ms. Reilly leads PhRMA’s policy and research department in the development and implementation of legislative, regulatory and political strategies to successfully navigate the ever-changing federal health care landscape, working to advance policies that encourage medical progress and patient access to the fruits of pharmaceutical innovation.

In addition to her public policy work, Ms. Reilly is a frequent presenter on biopharmaceutical industry-related issues and is an industry spokesperson. Ms. Reilly testified before the House Energy and Commerce Subcommittee on Health to discuss the importance of the reauthorization of the pediatric exclusivity program and the Food and Drug Administration Globalization Act.

Prior to joining PhRMA, she was counsel at the U.S. House of Representatives Committee on Commerce. And before joining the House Committee on Commerce, Ms. Reilly was chief of staff/counsel to Representative Jon Christensen (R-NE), a member of the House Ways and Means Committee.

Ms. Reilly is currently a board member for the Pharmacy Quality Alliance (PQA), a board member of the Personalized Medicine Coalition and a member of the Editorial Advisory Board of The Food and Drug Law Institute’s Policy Forum.

Ms. Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors and a J.D. from the University of Nebraska College of Law. She is a member of the Virginia Bar and currently resides in Alexandria, Virginia with her husband and their four children.

CONTACT INFORMATION
PhRMA Newsroom
Email: newsroom@phrma.org
Phone: 202-835-3460
James “Mit” M. Spears is executive vice president and general counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. Spears oversees the law department.

A former general counsel of the Federal Trade Commission with over 30 years of experience in both private practice and government, Spears offers broad-based expertise in health care, the life sciences and technology. In his most recent position as a partner at the Washington, D.C. office of the international law firm Ropes & Gray, LLP, he provided legal advice and strategy to biopharmaceutical companies on key industry issues. In addition to his work in the life sciences sector, Mit’s practice focused on antitrust and trade regulation, advertising and consumer law and litigation.

In addition to his tenure at the Federal Trade Commission, Mit served in various capacities at the U.S. Department of Justice including principal deputy assistant attorney general in both the Land and Natural Resources and Civil Divisions of the Department and acting assistant attorney general for Legal Policy. Mit’s legal career began as a staff assistant to Governor William P. Clements Jr. of Texas.

A native Texan, Mit received a B.B.A. from Texas Tech University and a J.D. from the University of Texas at Austin. Mit is an avid sailor and cyclist and currently resides with his wife, Kyle Gibson, in Washington D.C.
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The biopharmaceutical sector directly employs over 810,000 Americans, and invested more than $51 billion in 2014 to develop new medicines that help patients fight disease and live longer, healthier lives.

Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers and global trade organizations – to help ensure timely patient access to innovative treatments and cures.

As president and CEO of medical technology association AdvaMed, Ubl helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. In 2013, he was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation) and LUNGevity, the largest national lung cancer-focused nonprofit. He is routinely recognized as one of Washington’s most effective advocates by Washington political publications and has been named by Modern Healthcare one of the 100 Most Influential People in Healthcare.

Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals. He began his Washington career in the United States Senate.

CONTACT INFORMATION
PhRMA Newsroom
Email: newsroom@phrma.org
Phone: 202-835-3460
Michael Ybarra, M.D.
PhRMA
Senior Director, Alliance Development
Washington, DC

Michael Ybarra, M.D., FAAEM/FACEP is a board-certified emergency physician and senior director of alliance development at the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Ybarra is a graduate of Stanford University, Georgetown University School of Medicine and completed residency training at MedStar Washington Hospital Center.

After residency, Dr. Ybarra practiced academic emergency medicine. He was the site director for emergency medicine residents at MedStar Georgetown University Hospital. He also became the founding program director of the Health Policy Fellowship, which is a partnership with MedStar Georgetown University Hospital, the McCourt School of Public Policy and the Association of American Medical Colleges. He has authored a number of medical peer-reviewed publications, case reports and book chapters.

In addition, Dr. Ybarra has also served in various roles with the American Academy of Emergency Medicine including as president of the Resident and Student Association and director of the Young Physicians Section.

In 2014, Dr. Ybarra joined PhRMA as senior director of alliance development. In this capacity, he leads outreach to provider, multicultural and LGBT organizations. His issue areas include communications with health care professionals, health care delivery reform, adherence and the 340B drug discount program. He continues to practice clinically in the emergency department at MedStar Georgetown University Hospital.

CONTACT INFORMATION
PhRMA Newsroom
Email: newsroom@phrma.org
Phone: 202-835-3460
A nationally recognized health policy communicator, Robert Zirkelbach is senior vice president of communications for the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. At PhRMA, Zirkelbach is responsible for developing and executing the overall communications strategy for the organization and oversees a team that encompasses media relations, digital/social media, advertising, message development, internal communications and executive visibility. In this role, Zirkelbach serves as a lead spokesman for the association and manages multiple high-profile public affairs campaigns on the value of biopharmaceutical innovation, patient access to medicines and other industry priorities. Zirkelbach is also responsible for the strategic planning of PhRMA’s annual Research & Hope Awards – an annual event that honors patient advocates and researchers for their contributions fighting disease.

Zirkelbach is frequently quoted in national news publications and has appeared on numerous television and radio programs. He was recently named as one of The Hill's 2014 “Players to Watch” on health care issues.

Prior to joining PhRMA, Zirkelbach was vice president of strategic communications at America’s Health Insurance Plans. In this capacity, he served as the national spokesman for the health insurance industry and played a lead role in crafting the association’s communications strategy and public policy positioning throughout the health care reform debate and implementation of the Affordable Care Act. He oversaw a team responsible for the association’s media relations, public policy communications and grassroots and issue advocacy.

Previously, Zirkelbach was press secretary for Representative Jim Nussle (R-IA) where he served as a spokesman for the congressman and helped craft public messaging on all congressional-related matters. He is a graduate of Central College (IA) where he studied communications, business and public policy.
Latif Akintade, M.D., MBA

AbbVie

Vice President, Global Market Access
North Chicago, Illinois

Latif Akintade joined AbbVie as the head of global market access, global marketing in January 2013. Latif is responsible for leading the development and execution of the pricing and market access strategy for pipeline and on-market brands.

Prior to joining AbbVie, Latif was vice president global market access & medical affairs at Eisai from 2006 to 2013 with responsibility for pricing, market access and health economics and outcome research. He was European medical director at Eisai with responsibility for HEOR, market access and medical affairs from 2003 to 2006. Latif started his career at Eisai in 2000 as medical advisor for medical affairs & health economics. His career in the pharmaceutical industry began at Charterhouse Clinical Research Unit as a Clinical Research Physician. Prior to his career in the pharmaceutical industry, Latif was a General Surgeon in the U.K. National Health Service.

Latif earned his M.D, from St. George’s Hospital Medical School at the University of London and an MBA from Leonard N. Stern School of Business with a specialization in finance at New York University. He is a member of the Royal College of Surgeons Edinburgh and is a Fellow of the Faculty of Pharmaceutical Medicine U.K.

CONTACT INFORMATION

Latif Akintade, M.D., MBA
Email: latif.akintade@abbvie.com
Phone: 847-938-9116
Scott Brun, M.D.
AbbVie
Vice President, Pharmaceutical Development
North Chicago, Illinois

Scott has worked at Abbott and subsequently AbbVie for over 18 years in total, beginning his career as the first participant in the Abbott physician development program, a mini-fellowship in pharmaceutical medicine. He currently oversees pharmaceutical development at AbbVie, a global scientific and operational organization responsible for advancing a broad portfolio of early and late stage preregistrational pipeline compounds as well as marketed products within oncology, neurology, immunology, renal, infectious disease and women’s and men’s health therapeutic areas.

Over the years, Scott has directly overseen pharmaceutical development/medical affairs teams across a variety of therapeutic areas, including infectious disease, nephrology and immunology/inflammation and has contributed to the advancement of a variety of pipeline programs.

Scott earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign. He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.

CONTACT INFORMATION
Scott Brun, M.D.
Email: scott.c.brun@abbvie.com
Phone: 847-935-1293
Jeffrey R. Stewart

*AbbVie*

**Vice President, U.S. Commercial Operations**  
North Chicago, Illinois

Jeffrey R. Stewart is vice president, for U.S. Commercial Operations. Prior to AbbVie’s separation from Abbott in January 2013, he served as vice president, proprietary pharmaceuticals, United States.

Mr. Stewart joined Abbott in 1992 as part of TAP, Abbott’s former U.S. joint venture with Takeda Chemical Industries. Since his time with TAP, Mr. Stewart has held various leadership positions in Abbott’s U.S. and international pharmaceutical businesses, including divisional vice president, immunology; general manager, virology; general manager, United Kingdom; and divisional vice president, primary care.

He earned a bachelor’s degree in history from Princeton University.

**CONTACT INFORMATION**

Jeffrey R. Stewart  
Email: jeffrey.stewart@abbvie.com  
Phone: 847-938-3689
James P. Sullivan, Ph.D.
AbbVie
Vice President, Discovery
North Chicago, Illinois

James Sullivan, Ph.D., is vice president, discovery. In this role, he is responsible for AbbVie’s research efforts in a variety of diseases including cancer, Alzheimer’s disease, hepatitis C and a number of autoimmune disorders. He oversees a global network of scientists that includes AbbVie researchers at sites in the United States and Europe and external research partners around the world. Dr. Sullivan is a member of the R&D Leadership Team that has responsibility for the advancement of compounds in all stages of development, the Executive Licensing Steering Committee and the Scientific Governing Board for AbbVie. He is also an executive sponsor for the AbbVie Women in Science organization. Jim joined Abbott in 1991 and has held various positions in the R&D organization.

Jim has advanced multiple compounds into clinical development across multiple therapeutic areas including AbbVie’s recently launched combination product for HCV, the Bcl2 selective inhibitor, ABT-199, for oncology and a number of dual variable domain immunoglobulins (DVD-Igs) for rheumatoid arthritis and cancer. He has more than 130 scientific publications and is an inventor on 11 patents. He is an adjunct faculty member at Northwestern University in Chicago. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College in Dublin, Ireland and conducted post-doctoral research in neurobiology at Northwestern University.

CONTACT INFORMATION
James P. Sullivan, Ph.D.
Email: james.p.sullivan@abbvie.com
Phone: 847-938-3689
Reshma Kewalramani, M.D., FASN

Amgen Inc.

Head, U.S. Medical Organization
Vice President, Global Medical

Thousand Oaks, California

Reshma Kewalramani, MD FASN has worked at Amgen, since 2004 and has held roles of increasing responsibility within the organization. Currently, she serves as Vice President and Head of the U.S. Medical Organization. Her team has responsibility for the portfolio of molecules in the U.S., across all therapeutic areas including Oncology, Cardiovascular, Bone, Inflammation and Nephrology from the peri-launch phase through to end of the life cycle. Prior to this role, Reshma was the Vice President and Head of the Global Nephrology and Metabolic Therapeutic Area and oversaw ph2-ph4 clinical trials as well as other key aspects of drug development.

Prior to coming to Amgen, Reshma was a research fellow in Medicine at Harvard Medical School where she was involved in basic science research in transplantation in the field of co-stimulatory blockade and was a physician in the medical departments of the Massachusetts Eye and Ear Infirmary and the Massachusetts Institute of Technology. Reshma completed her internship and residency at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Reshma is also an alumnus of the Harvard Business School.

Reshma is the recipient of the American College of Physicians Associates Council Award, the American Medical Women’s Association Janet M. Glasgow Memorial Achievement Citation, and the Harvard Medical School Excellence in Teaching Award. She is a member of the Board of Directors of KHI (Kidney Health Initiative), on the Steering Committee of CTTI (Clinical Trials Transformation Initiative) and HBA 3BC (Healthcare Business Association) and a Fellow of the American Society of Nephrology. Reshma is also the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

Reshma received board certification in Internal Medicine in 2001 and in Nephrology in 2003.

CONTACT INFORMATION
Reshma Kewalramani, M.D., FASN
Email: reshmak@amgen.com
Phone: 805-447-6742
In May 2015, Mark Morgan, Executive Director of the Organized Customer Team, was appointed to lead Amgen’s new customer-facing model to improve coordination and access among the sales and marketing teams in order to better meet the needs of our customers at the national and local geographic level. Mark brings to the role a two decade history in the payer space with deep experience in the transformation occurring within the delivery system, the Affordable Care Act and Accountable Care Organizations.

Prior to joining Amgen, Mark began his payer career at Health Net of California in operations before assuming a leadership role in sales within their Labor & Trust segment. Mark was then asked to lead the Individual segment before becoming the Chief Product & Marketing Officer and finally the Chief Commercial Officer for Health Net.

In 2008 Mark moved to Anthem Blue Cross where he held several general management roles before becoming the COO and later the President of the California plan. Mark served on the board of the California Association of Health Plans, PriMed, CalChamber and the California Business Roundtable.

Mark holds a Bachelor of Science degree in Finance from California State University Northridge and a Master of Business Administration from Pepperdine University. Mark is married to Dawn and has a son and a daughter.

CONTACT INFORMATION

Mark Morgan
Email: markm03@amgen.com
Phone: 805-447-1092
Joshua J. Ofman, M.D., MSHS
Amgen Inc.
Senior Vice President, Global Value, Access and Policy
Thousand Oaks, California

Joshua J. Ofman, MD, MSHS is the senior vice president of global value access and policy at Amgen. Dr. Ofman is responsible for directing Amgen activities related to ensuring that Amgen products have a compelling value proposition and obtain market access from payers in each market, worldwide. These activities include global pricing, market access planning, global health economics, international government affairs, and health policy.

Dr. Ofman completed his undergraduate degree in the history and philosophy of science at University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. He then completed his internship and residency in internal medicine at UCLA Medical Center. Following his residency, Dr. Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services (MSHS) degree from the UCLA School of Public Health.

Dr. Ofman has served on several advisory boards for the American Gastroenterological Association, the American College of Physicians Clinical Efficacy Assessment Subcommittee, and is on the editorial board of the American Journal of Managed Care.

Dr. Ofman currently represents Amgen on the board of directors of California Healthcare Institute (CHI) and National Pharmaceutical Council (NPC).

Prior to joining Amgen in 2003 as head of U.S. health economics and outcomes research, Dr. Ofman was a member of the academic faculty in the Department of Medicine and Health Services Research, UCLA School of Medicine, Cedars-Sinai Medical Center. In this capacity, Dr. Ofman worked extensively with AHRQ’s Southern California Evidence-Based Practice Center and taught courses on the principles of evidence-based medicine. Dr. Ofman also served as the senior vice president of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

CONTACT INFORMATION
Joshua Ofman, M.D., MSHS
Email: jofman@amgen.com
Phone: 805-447-0787
Martin Zagari, M.D.
Amgen Inc.
Vice President, Global Health Economics
Thousand Oaks, California

Dr. Martin Zagari is vice president of global health economics at Amgen. In this role, he directs the planning, execution and scientific dissemination of worldwide economic and value evidence for Amgen’s entire product portfolio from early stage molecules to marketed products. Dr. Zagari joined Amgen in May of 2005.

Prior to Amgen, between 1997 and 2005, Dr. Zagari held various positions at Johnson & Johnson in health economics, medical affairs, and strategic marketing. These positions included: executive director in J&J corporate strategic marketing for the erythropoietic agents, medical director for erythropoietic treatments in oncology at Ortho Biotech, and director positions in health economics.

Between 1994 and 1997, Dr. Zagari worked in health economics and outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco.

Martin received his MD from Stanford University, an MBA from Rutgers University, and BS in Biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology.
Jeffrey Bloss, M.D., is senior vice president, Astellas medical affairs, Americas, at Astellas Pharma Global Development, Inc., a global research-based pharmaceutical company committed to serving unmet medical needs in oncology, immunology, infectious diseases, urology, neuroscience, DM complications and kidney diseases.

Since joining Astellas in 2012, Dr. Bloss has been responsible for leading the America’s regional medical affairs function, including medical information and publications, therapeutic area medical directors, medical scientific liaisons, health economics and clinical outcomes research, independent medical education and medical affairs operations. Dr. Bloss has also assumed direct oversight of the medical affairs functions in Canada and Latin America.

Prior to joining Astellas, Dr. Bloss served as vice president and head, oncology global medical affairs at GlaxoSmithKline. Prior to joining GlaxoSmithKline oncology, Dr. Bloss held positions as chief medical director at Xencor, vice president of clinical development at Onyx Pharmaceuticals, group medical director at Genentech (Tarceva – clinical development leader) and medical director at Eli Lilly and Company.

Dr. Bloss started his career in the United States Air Force, holding executive positions in the department of obstetrics, gynecology and gynecologic oncology. Following his 15-year service to his country, Dr. Bloss continued in the field of obstetrics, gynecology and gynecologic oncology at the University of Missouri – Columbia Health Sciences Center.

Dr. Bloss received his Bachelor of Science degree at Juniata College in Huntingdon, Pennsylvania. He received his medical degree from Thomas Jefferson University, Jefferson Medical College. He completed his residency in obstetrics and gynecology at the Wilford Hall USAF Medical Center in Lackland, Texas, and completed a gynecologic oncology fellowship at the University of California, Irvine.
Shontelle Dodson, Pharm.D., is vice president of medical excellence within medical affairs, global. In this role, she oversees medical communications, scientific publications, health economics and outcomes research, and medical affairs research and grants functions. Under her leadership, the health outcomes group has pioneered multiple, innovative real-world data projects, including two national registries in prostate cancer and overactive bladder, as well as partnered research with leading managed care and academic organizations.

Dr. Dodson has extensive clinical research and analytics experience in the health care and pharmaceutical industries. Prior to joining Astellas in 2012, Dr. Dodson was vice president of medical affairs at GTx, Inc., where she led a cross-functional business unit to progress a new molecular entity into global Phase 3 clinical development.

Previously, she spent 11 years at Pfizer in various leadership roles in women’s health, urology and sexual medicine.

Dr. Dodson holds a Doctor of Pharmacy from Mercer University School of Pharmacy and completed a postdoctoral residency at the Department of Veterans Affairs Medical Center in Nashville, Tennessee. In 2014, Dr. Dodson received the National Healthcare Business Women’s Association Rising Star award, which honors women that have demonstrated noteworthy achievements and proven attention to furthering their careers. Dr. Dodson also serves on the board of directors of the Society for Women’s Health Research, which advocates for greater public and private funding for women’s health research and the study of biological differences that affect the prevention, diagnosis and treatment of disease.
Martin Golden, J.D., MBA
Astellas Pharma US, Inc.
Vice President, Government Affairs
Northbrook, Illinois

Martin “Marty” Golden, J.D., MBA, currently serves as vice president, government affairs for Astellas Americas. In this role, Golden leads all Astellas federal and state government affairs, government strategy and policy development in the Americas region.

Prior to his current role, Golden served as vice president, hospital and transplant sales. Golden joined Astellas in 2006 and has also held roles in new product planning and strategy. Prior to joining Astellas, Golden served in a number of positions of increasing responsibility across several disciplines for Novartis, Johnson & Johnson and Bristol-Myers Squibb.

Golden holds a Bachelor of Business Administration degree from the University of Iowa, Iowa City, Iowa, a Juris Doctor degree from John Marshall Law School, Chicago, Illinois, and a Masters of Business Administration from Northwestern University-Kellogg School of Management, Evanston, Illinois.

CONTACT INFORMATION
Karl Uhlendorf
Email: karl.uhlendorf@astellas.com
Phone: 202-741-1968
Walt Johnston is vice president, marketing and strategic new product planning for Astellas Pharma US, Inc., a global research-based pharmaceutical company committed to serving unmet medical needs in oncology, immunology, infectious diseases, urology, neuroscience and DM complications and kidney diseases.

Johnston leads all marketing activities and programs across several therapeutic areas of the Astellas US business to ensure superior commercial performance. He has primary responsibility for urology, transplant, cardiovascular and anti-infective markets. Johnston has over 20 years of experience in the pharmaceutical industry and is a member of the Astellas Portfolio Strategic Executive Committee.

Prior to joining Astellas in 2008, he held increasingly more senior positions in marketing and sales with Pfizer Pharmaceuticals in New York. Johnston started his career at Pfizer in 1990 as a sales representative and moved through positions of increasing responsibility until promoted to senior director, group leader CV marketing in 2006. In this position, he led the largest portfolio of products in Pfizer.

Johnston is a native of Pittsburgh, Pennsylvania, and earned his Bachelor of Arts at Lafayette College in Easton, Pennsylvania. He earned his MBA at Boston College in Boston, Massachusetts. He lives in the Chicago area with his wife and four children (three sons and one daughter).
Mark Reisenauer has been vice president of oncology sales and marketing at Astellas Pharma US, Inc., since May 2011. Reisenauer is responsible for all U.S. commercial activities supporting marketed products, Astellas Pharma’s oncology co-promotion partners and leads commercial planning for early stage development compounds.

The majority of his 20-plus year career has been committed to oncology therapies, where he has had sales and marketing responsibilities in a variety of capacities (domestic and global) at Abbott, Pharmacia, Bristol-Myers Squibb and Zeneca. He served as chief commercial officer and senior vice president of Micromet, Inc., beginning in September 2007, and was involved in investor and public relations, clinical strategy, business development and commercial launch planning.

Reisenauer joined Micromet from Abbott, where he served as the general manager of the oncology franchise from 2002 to 2006. He served as divisional vice president and general manager of the Neuroscience franchise from 2006 to September 2007. Before joining Abbott, he served as the director of marketing for breast cancer (portfolio lead) and the director of breast cancer products at Pharmacia from 1999 to 2002. From 1997 to 1999, he served as the associate director of oncology global marketing at Bristol-Myers Squibb, and from 1988 to 1997, he held various positions in sales and oncology marketing at Zeneca. Reisenauer holds a BA degree in political science from the University of Wisconsin.

CONTACT INFORMATION

Karl Uhlendorf
Email: karl.uhlendorf@astellas.com
Phone: 202-741-1968
Kenton Stewart possesses more than 25 years of progressively responsible experience in the pharmaceutical industry and currently serves as vice president of health systems at Astellas Pharma US (APUS) comprised of account management, contracts and pricing, reimbursement and market access, health systems marketing, trade sales and operations. During his 10 years with APUS, he has also served as senior director, contracts and pricing and senior national director of corporate, hospital and institutional accounts.

Prior to joining Astellas, Stewart was senior director, licensing and business development at TAP Pharmaceuticals, where he led corporate business development and acquisitions. Previous to this, Stewart was national director of national managed care accounts.

From 1991 to 2000, Stewart held various positions with Abbott Laboratories, including sales, sales management, product management and marketing manager.

Stewart holds a Master of Business Administration degree and a Bachelor of Business Administration degree in marketing.
Christie Bloomquist leads AstraZeneca’s Washington D.C. office as vice president, federal government affairs & policy (FGAP), U.S. corporate affairs. Under Christie’s leadership, FGAP is responsible for engaging with federal government stakeholders on AstraZeneca business priorities. This includes AstraZeneca’s engagement with the U.S. department of Health and Human Services and Congress on innovative payment arrangements.

Prior to leading FGAP, Christie was the head of policy & executive branch advocacy, U.S. corporate affairs for AstraZeneca and also worked as a senior member of the federal government affairs team during the consideration, passage and implementation of the Affordable Care Act.

Christie’s background is as a health care regulatory attorney, with a focus on the pharmaceutical industry. She practiced law for 15 years and was a partner in two global law firms in the D.C. area.

Christie earned her undergraduate degree from Tulane University and her Juris Doctor and Master of Health Administration from Washington University in St. Louis.
Dave Fredrickson
AstraZeneca

Vice President, Specialty Care
Gaithersburg, Maryland

Dave is responsible for leading the U.S. specialty care business, which includes driving business-unit and product performance and building high-performing teams in oncology, infectious disease and neuroscience markets to meet business goals.

Dave previously served as business unit director, oncology-hematology at Roche/Genentech, where he worked for nine years, most recently in Spain. In this role, he led a 200-person sales and marketing organization across 10 brands and 3 business units. Prior to that, he served as business unit manager in Spain and held a number of oncology marketing and sales leadership roles at Genentech in San Francisco, including division sales director and marketing director. He also led early commercialization strategies and life-cycle planning for key brands across multiple disease areas.

Before joining Genentech, Dave was named as a partner candidate and served as a global account manager for the Monitor Group, LLC, a global strategy consultancy where he served for nine years. He was the co-lead of Monitor’s biotechnology practice, a member of the western U.S. leadership team and a co-founder of the company’s offices in San Francisco.

CONTACT INFORMATION
Christine Bloomquist, J.D.
Email: christine.bloomquist@astrazeneca.com
Phone: 202-350-5542
Paul Hudson
AstraZeneca
President, U.S. and Executive Vice President, North America
Wilmington, Delaware

Paul Hudson is responsible for leading AstraZeneca’s commercial operations in North America and represents the region as a member of the senior executive team. In this capacity he is accountable for driving growth and maximizing contribution of North America to AstraZeneca’s global business.

Prior to his role in North America, Paul served as representative director and president of AstraZeneca K.K., the Japanese subsidiary of AstraZeneca PLC. He has served as a standing board member of JPMA (Japan Pharmaceuticals Manufacturers Association) and EFPIA (European Federation of Pharmaceutical Industries and Associations) in Japan. Previously Paul was president of AstraZeneca’s business in Spain. He joined AstraZeneca in 2006 as vice president and primary care director, U.K.

Before AstraZeneca, Paul worked for Schering Plough, where he held roles of increasing seniority, including leading biologics global marketing, based in the U.S. He began his career at GlaxoSmithKline U.K. and Sanofi-Synthelabo U.K. with roles in sales and marketing.

CONTACT INFORMATION
Christine Bloomquist, J.D.
Email: christine.bloomquist@astrazeneca.com
Phone: 202-350-5542
Philip Blake
Bayer
President, U.S. and Head of Americas Region, Pharmaceuticals
Whippany, New Jersey

Philip Blake was appointed senior Bayer representative, U.S. in July 2012. He is responsible for all U.S. activities of the worldwide Bayer Group.

In addition, Blake serves as regional head of Bayer Pharmaceuticals for the Americas, a role he assumed in October 2015. In this role, he leads the pharmaceuticals division of Bayer for Canada, the United States and Latin America.

Previously, Blake served as president and CEO, Bayer Inc. and head of Bayer HealthCare in Canada.

In his 30-plus-year career with Bayer, Blake has held leadership positions around the world focusing on global strategic product marketing, business development, clinical planning, product development and sales management.

Blake obtained his degree at Bristol University and undertook further executive training at The Open University, INSEAD (Institut européen d’administration des affaires) and Wharton Business School. He is a chartered corporate director – earning this designation in 2006 from the Directors College at the DeGroote School of Business, McMaster University.

CONTACT INFORMATION
Steven Immergut
Email: steven.immergut@bayer.com
Phone: 202-572-8613
Shannon Campbell has been vice president and general manager, oncology at Bayer, since 2008. Shannon is responsible for all U.S. commercial activities supporting the oncology business and is a member of the U.S. pharmaceutical executive team, Bayer’s global oncology leadership team as well as other operational and governance leadership bodies.

Shannon has focused on oncology or specialty markets for most of her 25+ years in the pharmaceutical industry and has a strong track record of leadership, innovation, alliance relationships and operational experience. She joined Bayer in 2005 to establish an oncology business and lead the U.S. launch for Nexavar.

Prior to joining Bayer, Shannon was at Abbott, where she worked primarily to establish an oncology commercial business unit and later lead the marketing activities for HUMIRA.

Prior to joining Abbott, Shannon spent more than a decade with the Pharmacia heritage companies (Pharmacia & Upjohn, The Upjohn Company), where she held a variety commercial leadership positions in the United States, Australia and the United Kingdom. Shannon has successfully driven many new product launches on a global basis and maintained a strong focus and commitment to addressing the evolving needs of the healthcare community and patients that she serves.

Contact Information

Rose Talarico
Email: rose.talarico@bayer.com
Phone: 862-404-5302
Habib Dable
Bayer
President, U.S. Pharmaceuticals
Whippany, New Jersey

Habib Dable is president of U.S. pharmaceuticals for Bayer, a role he has held since October 2015.

Most recently, Habib was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, a role he held since 2013 and in which was responsible for overseeing four therapeutic areas for the company – hematology, oncology, ophthalmology and neurology.

Habib began his career at Bayer in 1994 as a sales representative in Canada, where he later moved on to various sales and marketing roles with increasing management responsibility. He then spent two years at Bayer HealthCare’s office in Osaka, Japan, as head of strategic planning before moving to the United States and serving as director of international sales and marketing. He was later appointed vice president and regional business unit head, responsible for Latin America, Canada, the Asia Pacific region and Japan.

From 2008 to 2012, Habib headed Bayer’s global therapeutic area team for neurology / ophthalmology, and he was vice president for ophthalmology and headed the global launch team for EYLEA® (aflibercept), the company’s treatment for macular degeneration.

Habib earned a Master of Business Administration from the University of New Brunswick in Canada, where he also completed his undergraduate study. He is married with two children and resides in New Jersey. Habib’s personal interests include jogging, squash, golf, youth hockey and the classic English card game, whist.

CONTACT INFORMATION

Steven Immergut
Email: steven.immergut@bayer.com
Phone: 202-572-8613
Kevin O’Leary joined Bayer in 2014 as vice president, strategic pricing and reimbursement. He is responsible for U.S. pricing, reimbursement strategy, hubs providing reimbursement support to providers and patients, field reimbursement teams and patient assistance programs.

Kevin came to Bayer from IMS Consulting Group, where he was a senior principal for five years in the pricing and market access practice. He spent the previous 11 years at Roche Pharmaceuticals, where he served in several senior roles related to pricing, reimbursement and market access. His experience spans orals, self-injectables and infused products in disease areas including diabetes, hemophilia, MS, influenza, anemia, rheumatoid arthritis, oncology, hepatitis C, obesity, osteoporosis, CNS and transplant.

Kevin also has worked in managed care, state government (where he established and ran New Jersey’s groundbreaking health insurance reform programs), Congress and law. His experience gives him a unique, in-depth understanding of commercial, political and regulatory currents in the U.S. pharmaceutical market.

Kevin earned a bachelor’s degree in English and economics and a J.D., *cum laude*, from Georgetown University. He and his wife, Jane, have been married for 29 years and have four daughters.
David Miller has nearly 25 years of executive and operational roles in the biopharmaceutical industry. He has been responsible for the development and execution of complex pricing and reimbursement strategies for numerous products in the U.S. and ex-U.S. markets. He currently is senior vice president of global market access at Biogen with responsibility for securing pricing, reimbursement and access of Biogen products worldwide. Prior to joining Biogen in 2011, he was an independent consultant delivering strategies to secure pricing, reimbursement and access on behalf of pharmaceutical clients. He previously worked at Elan, holding roles as vice president of pharmacoeconomics, managing director and head of international operations.

Dr. Miller began his pharmaceutical industry career at GlaxoSmithKline and assumed increasing responsibilities in the U.S. and ex-U.S. towards becoming vice president of global health outcomes. A dual U.S./U.K. citizen, he has lived and worked internationally for over half of his career. Dr. Miller is the author or co-author of more than 70 scientific publications and is a frequent speaker on industry policy issues related to pricing, reimbursement and access. He is director on the National Pharmaceutical Council Board of Directors, is a member of advisory boards at the University of Maryland Baltimore, University of Washington and Tufts University and a board member of the Walther Foundation, a charitable organization supporting youth education.

Dr. Miller served as a director on the board of directors of Elan Pharma Ltd., was vice chair of PhRMA’s health outcomes committee and was chair of the board of grants for the American Foundation for Pharmaceutical Education. He holds a degree in pharmacy from the University of Iowa and earned his Ph.D. in pharmacy administration at the University of Maryland - Baltimore where he studied health economics and policy.
Dr. Sandrock is Biogen’s executive vice president, neurology discovery & development center, neurodegeneration therapeutic area and chief medical officer and has served in this position since November 2015. Dr. Sandrock has served as group senior vice president from May 2014 to October 2015 as well as chief medical officer since February 2012.

Since joining Biogen in 1998, Dr. Sandrock has held several senior executive positions, including senior vice president of development sciences, senior vice president of neurology research and development and vice president of clinical development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology and a clinical fellowship in neuromuscular disease and clinical neurophysiology (electromyography) at Massachusetts General Hospital.
Kathleen Tregoning
Biogen Inc.
Senior Vice President, Corporate Affairs
Washington, D.C.

Kathleen Tregoning has served as senior vice president, corporate affairs at Biogen since December 2015, overseeing the company’s policy and advocacy engagement, corporate and employee communications, media relations, product communications and philanthropy/community outreach on a global basis.

Ms. Tregoning brings to the role more than 20 years of experience in policy development and advocacy, stakeholder outreach and external engagement. She joined Biogen in 2006 as vice president, public policy & government affairs. Over the course of nine years, she built the company’s first global government affairs team to advance policies that enable the delivery of innovative biopharmaceutical products to patients. Her team has served as strategic partners to divisions throughout the company to evaluate business issues and develop and execute advocacy strategies to advance Biogen’s policy agenda.

Prior to joining Biogen, Ms. Tregoning was a professional staff member in the U.S. Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy & Commerce Committee and the Senate Budget Committee. In these positions she was a key resource for members of Congress on a wide range of health care issues, including Medicare, Medicaid, prescription drugs, disease management, health care information technology and post-acute care.

Ms. Tregoning received her undergraduate degree in international relations from Stanford University and her master’s degree in public policy from the Kennedy School of Government at Harvard University. She currently serves on the boards of the Massachusetts Biotechnology Council (MassBio) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).

CONTACT INFORMATION
Kathleen Tregoning
Email: kathleen.tregoning@biogen.com
Phone: 202-383-1444    Cell: 202-352-5505
James Baxter, Pharm.D., Ph.D.
Boehringer Ingelheim Pharmaceuticals, Inc.

Senior Vice President, Development
Ridgefield, Connecticut

Jim earned a B.S. in Pharmacy from the University of Rhode Island (1982), and a Pharm.D. (1984) and later a Ph.D. (Pharmaceutics; 1989) from the University of Buffalo. He joined Pfizer Central Research (Groton, CT) in 1989, where he worked on the discovery and development of central nervous system drug candidates. In 2000, he was named Groton site head for global pharmacokinetics, dynamics and metabolism and in 2004 moved to the pharmaceutical sciences group where he served as site head in Groton, and later as global head of the portfolio, strategy and operations group for Pharmaceutical Sciences.

Jim joined Boehringer Ingelheim (BI) in Ridgefield, Connecticut in 2007 as senior vice president, development U.S. In this role, he oversees non-clinical development activities in support of BI’s global drug development projects, covering a wide variety of new drug candidates for the treatment of immunologic disorders, diabetes and other medical conditions. Jim and his wife, Jamie, have been married for 29 years and are the proud parents of 2 adult children.

CONTACT INFORMATION
James Baxter, Pharm.D., Ph.D.
Email: james.baxter@boehringer-ingelheim.com
Phone: 203-778-7350
Paul Fonteyene
Boehringer Ingelheim Pharmaceuticals, Inc.

President and Chief Executive Officer
Ridgefield, Connecticut

Paul Fonteyene was appointed president and CEO of Boehringer Ingelheim USA Corp. and U.S. country managing director on January 1, 2012. Paul has been employed by Boehringer Ingelheim since 2003. Leading up to this role, Paul was responsible for global marketing of BI’s pharmaceutical business and, before that, its pharmaceutical business in the U.S.

Prior to 2003, Paul held marketing and sales positions of increasing responsibility at Abbott Labs and Merck & Co. Inc.

Born in Brussels, Belgium, Paul earned an M.S. in chemical engineering from University of Brussels in 1985 and an MBA from Carnegie Mellon University in 1987.

He is currently on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and is a member of the New England Chapter of CEO’s Against Cancer serving as vice chair. In the past he has served as chairman of the National Pharmaceutical Council.


CONTACT INFORMATION
Paul Fonteyene
Email: paul.fonteyene@boehringer-ingelheim.com
Phone: 203-798-5010
Dr. David S. Memel has a strong record of leadership, innovation and operating experience in multinational pharmaceutical, diagnostics, provider and payer organizations. He is skilled in traversing the intersection of business, medicine, science and technology; and is an effective, open and honest communicator, enabling him to engage key stakeholders in a shared vision that drives innovation and growth.

As the vice president of health economics and outcomes research for Boehringer Ingelheim Pharmaceuticals, Inc. (BI), Dr. Memel leads the continued evolution of BI’s development and delivery of actionable, evidence-based solutions to inform key stakeholders’ decisions about patient access to and appropriate use of BI’s medicines. Dr. Memel also serves as a key participant in BI’s global efforts to expand engagement in real world evidence generation, is a major contributor to BI’s strategy for innovative collaborations with payers and health care delivery systems and played a key role in development of BI’s U.S. biosimilars strategy.

Prior to joining BI, Dr. Memel’s positions included chief medical officer and senior vice president of analytics for LifeCare, Inc., head of informatics for Aetna, Inc., global chief medical officer for Roche Professional Diagnostics, director of medical data management and analytics and director of health economics and outcomes research for Roche Pharmaceuticals and corporate vice president of information management and quality improvement for PeaceHealth, a multi-state integrated delivery system.

Dr. Memel received his B.S. and M.D. from the University of California at Los Angeles. He also holds an M.S. in Medical Informatics from the University of Utah School of Medicine and an MBA from a joint international program at Cornell University in the U.S. and Queen’s University in Canada. Dr. Memel also completed a fellowship in clinical effectiveness research at the Harvard School of Public Health.

**David S. Memel, M.D., M.S., MBA**

*Boehringer Ingelheim Pharmaceuticals, Inc.*

Vice President, Health Economics and Outcomes Research

*Ridgefield, Connecticut*

**CONTACT INFORMATION**

David S. Memel, M.D., M.S., MBA

Email: david.memel@boehringer-ingelheim.com

Phone: 203-798-5557
Dr. Palmisano currently serves as vice president, regulatory affairs, Boehringer Ingelheim Pharmaceuticals Inc. (BI), where she is responsible for oversight and leadership of the regulatory affairs organization in the U.S. Prior to joining BI in August 2010, Dr. Palmisano served as assistant vice president, global regulatory affairs and regulatory head for cardiovascular/metabolism, GI and anti-infective/anti-viral at Wyeth/Pfizer. Her move into regulatory affairs followed several years at Merck as senior medical director of clinical development, including oversight of all clinical development for Phase 3b-4 for cardiovascular/lipids and endocrinology products.

Dr. Palmisano is a graduate of Columbia University College of Physicians & Surgeons and a specialist in diabetes. Prior to joining Industry, Dr. Palmisano had extensive experience in academic medicine and clinical research as senior physician, the Joslin Diabetes Center, Harvard Medical School and assistant professor of medicine and endocrinology, SUNY Health Science Center at Brooklyn, where she served as director of the diabetes clinic, Kings County Hospital Center, New York City.

Dr. Palmisano represents BI as a member of the PhRMA Regulatory Affairs Coordinating Committee (RACC). Her special interests include drug development in pediatric populations, serving as the PhRMA RACC sponsor for the Pediatric Charter and as group leader for the ICH Expert Working Group for the update for E11 pediatric drug development.
Christopher Boerner, Ph.D.
Bristol-Myers Squibb Company

President and Head, U.S. Commercial Operations
Plainsboro, New Jersey

Christopher Boerner, Ph.D., is currently the president and head of the U.S. commercial business at Bristol-Myers Squibb (BMS). He joined BMS in February 2015.

Prior to this role, Dr. Boerner served as the executive vice president of commercial for Seattle Genetics, Inc., where he was responsible for leading all commercial activities for the company. Previously, he was its senior vice president of commercial and vice president of marketing. Before joining Seattle Genetics, Inc., Dr. Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he was with Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy and associate director of oncology market development. Prior to Genentech, Dr. Boerner was with McKinsey & Company, a global strategic management consulting firm, where he served global pharmaceutical and biotechnology clients.

Dr. Boerner received his Ph.D. and Master of Business Administration from the Haas School of Business at the University of California, Berkeley and holds an AB in economics and history from Washington University in St. Louis.

CONTACT INFORMATION
Christopher Boerner, Ph.D.
Email: christopher.boerner@bms.com
Phone: 609-897-4045
Murdo Gordon
Bristol-Myers Squibb Company

Senior Vice President and Head, Worldwide Markets
Princeton, New Jersey

Murdo Gordon co-leads the Bristol-Myers Squibb commercial organization and is head of worldwide markets. In this role, he has operational responsibility for each of the markets and regions where Bristol-Myers Squibb conducts business. Murdo works closely with country and regional general managers and their local teams to maximize the impact Bristol-Myers Squibb products have on the lives of patients.

Murdo joined Bristol-Myers Squibb in 1989. He spent the first 14 years of his career in Canada, where he held positions of increasing responsibility in sales and marketing. Murdo moved to the United States in 2003, where he worked in a number of different therapeutic areas, such as cardiovascular, neuroscience, access/government affairs, oncology and immunology, as well as president of Bristol-Myers Squibb in the United States.

Murdo is a member of the board of directors of the Robert Wood Johnson University Hospital System. He maintains an active interest in global and U.S. health care policy and how different stakeholders can improve the efficiency and cost effectiveness of health care delivery.

Murdo received a Bachelor of Science in cell and molecular biology from Concordia University, Montreal, and also attended the general management program, CEDEP at INSEAD, Fontainebleau, France.

CONTACT INFORMATION

Murdo Gordon
Email: murdo.gordon@bms.com
Phone: 609-252-5320
Fouad Namouni, M.D.

Bristol-Myers Squibb Company

Head, Medical
Princeton, New Jersey

Fouad Namouni, M.D., is head of medical at Bristol-Myers Squibb (BMS). In this position, he has responsibility for ensuring the safe and appropriate use of the company’s products and for providing support for the near-term pipeline. He is accountable to Francis Cuss, chief scientific officer, and is a member of the R&D executive leadership team and the commercial leadership team.

Over the course of his career at BMS, Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs at both national and international levels.

Before taking on his current role, Fouad was head of development for Opdivo® and Yervoy®. Under his leadership, Opdivo received approval for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) and unresectable or metastatic melanoma, as well as expanded approval in previously treated NSCLC in the United States and European markets. Yervoy received approval for the adjuvant treatment of stage III melanoma, and Opdivo plus Yervoy was approved for the treatment of metastatic melanoma.

Prior to this, Fouad was responsible for the development of the epidermal growth factor inhibitor Erbitux® and the IgG1 monoclonal antibody necitumumab. He also served as global, U.S. and E.U. medical lead in several BMS oncology projects. Fouad joined BMS France in 1999 as Taxol® life cycle manager.

Earlier in his career, Fouad was a pediatric oncologist at Institut Curie in Paris, France, where his focus was on developing agents for the treatment of pediatric tumors. He received his medical degree from the University of Annaba Medical School in Algeria and pediatrics degree from Université Rene Descartes in Paris, France. He also received his pediatric oncology and hematology degree and a M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

CONTACT INFORMATION

Fouad Namouni, M.D.
Email: fouad.namouni@bms.com
Phone: 609-252-5450
Kevin Trapp
Bristol-Myers Squibb Company

Head, Product, Portfolio and Access Strategy
Princeton, New Jersey

Kevin Trapp is head of product, portfolio and access strategy for worldwide commercialization at Bristol-Myers Squibb. Kevin has responsibility for developing global strategies to bring medicines from pipeline to patients, with close collaboration across R&D, business development and manufacturing. Kevin is also responsible for developing and leading a global market access strategy focused on new and innovative mechanisms for patient access to medicines. He chairs the Worldwide Access Council and is a member of the company’s commercial, senior R&D and pipeline strategy leadership teams. Prior to this role, Kevin led Bristol-Myers Squibb’s global launch of its hepatitis C portfolio.

Kevin joined Bristol-Myers Squibb in 1989 and has held positions of increasing responsibility in finance and strategic planning. He began work on the oncology/immunology franchise, where he led negotiations on a ground-breaking collaboration to develop Atripla®, a once-daily oral HIV therapy. In 2006, he joined the neuroscience business leading all strategic and tactical elements of U.S. marketing promotions for Abilify and directed the launch of three new formulations and one new indication. He was the key commercial liaison with Japanese partner, Otsuka, and provided strategic vision for a division of over 1000 employees.

Kevin also led multiple business units in the United States, including neuroscience, immunoscience and virology providing general management across specialty, primary care, small molecules and biologics.

Kevin received a B.S. in accounting from The University of Connecticut School of Business and also attended the general management program, CEDEP at INSEAD, Fontainebleau, France.

CONTACT INFORMATION

Kevin Trapp
Email: kevin.trapp@bms.com
Phone: 609-419-5521
Mr. Alles became president and chief operating officer in August 2014. He was formerly the executive vice president and global head of hematology and oncology since December 2012 following his promotion to executive vice president and chief Commercial officer on February 15, 2012. Mr. Alles joined Celgene in April 2004 and served as vice president, global marketing until March 2009 when he became president of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011.

Mr. Alles previously served as vice president for the U.S. oncology business unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles during his 11-year career there. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a captain in the United States Marine Corps, Mr. Alles started his 28-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles currently serves as a director for Gilda’s Club NYC, a nonprofit organization helping people with cancer, and as a trustee of The Healthcare Institute of New Jersey.
Richard Bagger
Celgene Corporation

Executive Vice President, Corporate Affairs and Market Access
Summit, New Jersey

Richard Bagger is executive vice president of corporate affairs and market access for Celgene Corporation, a multinational biopharmaceutical company focusing on the discovery, development and commercialization of treatments for cancer and severe immune-inflammatory conditions. A member of Celgene’s Management Committee, Rich is responsible for advancing patient access to Celgene therapies and driving recognition of the value of Celgene innovation through government relations, public policy, communications, patient advocacy and market access activities around the world. Rich most recently served for two years as chief of staff for New Jersey Governor Chris Christie, responsible for managing implementation of the Governor’s policy agenda and priorities.

After leaving state government, Rich was appointed by Governor Christie to be a commissioner of the Port Authority of New York and New Jersey, where he serves as chairman of the finance committee. Previously, Rich was employed by Pfizer Inc. for more than 16 years in a series of positions of increasing responsibility within the company’s U.S. pharmaceuticals, corporate affairs and worldwide pharmaceuticals divisions. From 2006 to 2009, he served on Pfizer’s senior most management team as senior vice president, worldwide public affairs and policy.

CONTACT INFORMATION
Richard Bagger
Email: rbagger@celgene.com
Phone: 908-673-9855
Joel Beetsch, Ph.D.
Celgene Corporation

Vice President, Patient Advocacy
Summit, New Jersey

Joel Beetsch currently holds the position of vice president of patient advocacy within the Celgene corporate affairs department. In this position, Dr. Beetsch leads the global development and execution of a coordinated patient-focused advocacy strategy working with multiple patient, provider, payer and policy organizations to foster safe and effective solutions to health care challenges. These efforts drive the assurance that patient access to health care solutions and medical innovation and are valued and advanced.

During his 15-year tenure in the biopharmaceutical industry, Dr. Beetsch has held several medical and corporate affairs positions. Joel has professional interests in patient-focused care coordination, health policy and the use of health information technology.

Joel earned his doctorate in neurobiology/biochemistry from the Boonshoft School of Medicine at Wright State University. Following his doctoral work, Dr. Beetsch was further trained in cellular physiology at the Washington University School of Medicine in St. Louis.

CONTACT INFORMATION
Joel Beetsch, Ph.D.
Email: jbeetsch@celgene.com
Phone: 908-673-9325
Brian Gill

Celgene Corporation

Vice President, Corporate Communications
Summit, New Jersey

Brian Gill has been responsible for corporate communications at Celgene since 2003. Prior to joining Celgene, Mr. Gill served for more than eight years as managing director for communication firms in New York City creating global communications programs for health care and biotech companies.

Prior to that, he held director and management positions, both domestic and internationally, with leading health care and biotech companies. He also spent time on Wall Street as a junior sell-side analyst following health care and biotech companies.

CONTACT INFORMATION
Brian Gill
Email: bgill@celgene.com
Phone: 908-673-9530
Alex Azar is president of Lilly USA, the largest affiliate of Eli Lilly and Company, producing almost half of its revenue.

Azar’s responsibilities include direction over Lilly USA, the legal entity that houses the sales and marketing operations of the company’s entire U.S. commercial business: the U.S. biomedicines, diabetes and oncology business units. He also directly leads U.S. Biomedicines, the affiliate’s largest division, encompassing the areas of neuroscience, cardiovascular health, men’s health, musculoskeletal, autoimmune disease, Alzheimer’s disease, pain and managed health care services.

Azar served as vice president of Lilly’s U.S. managed health care services and Puerto Rico from 2009 to 2011. He joined Lilly in 2007 as senior vice president of corporate affairs and communications.

Before his tenure at Lilly, Azar was the Deputy Secretary of the U.S. Department of Health and Human Services (2005-2007), where he was the number two official and chief operating officer for the largest civilian cabinet department in the U.S. government, with a budget of $698 billion and more than 66,000 employees reporting up to him. From 2001 to 2005, he served the department as general counsel.

Azar earned a bachelor’s degree summa cum laude in government and economics from Dartmouth College in 1988 and a law degree from Yale University in 1991. After law school, he clerked for Associate Justice Antonin Scalia on the Supreme Court of the United States.

Azar is a member of several boards, including the Biotechnology Industry Organization (chair of the reimbursement committee), the Healthcare Leadership Council (treasurer), the American Council on Germany and the Indianapolis Symphony Orchestra. He lives in Indianapolis with his wife and two children.

CONTACT INFORMATION
Kelley Murphy
Email: murphy_kelley@lilly.com
Phone: 317-701-4007
Enrique Conterno was named senior vice president and president of Lilly Diabetes, effective November 1, 2009. Prior to this role, Conterno served as president of Lilly USA, the company’s largest affiliate.

Born in Lima, Peru, Conterno earned his bachelor’s degree in mechanical engineering from Case Western Reserve University in 1989 and his MBA from Duke University in 1992.

Conterno joined Lilly as a sales representative in 1992. From 1993 to 1995, he held roles as a financial analyst, marketing associate and business development manager. In 1996, Conterno was named sales and marketing director for Lilly Peru, and in 1998, he became sales and marketing director for the Brazil affiliate. In 2000, Conterno was named executive director of marketing for the intercontinental region and Japan. In 2003, Conterno became president and general manager for Lilly’s operations in Mexico. In July 2006, Conterno was named vice president of Lilly USA’s neuroscience business unit, and he assumed the role of Lilly USA senior vice president of health care professional markets in 2008. In January 2009, he was named president of Lilly USA.

Conterno is chairman of the board at the Greater Indianapolis Chamber of Commerce and a member of the board of governors at the American Red Cross. He is a member of the board of visitors for Duke University’s Fuqua School of Business and a member of the board of directors for the National Association of Manufacturers.

He and his wife, Kathleen, have three children: Francesca, Jacqueline and Nicholas.

CONTACT INFORMATION
Kelley Murphy
Email: murphy_kelley@lilly.com
Phone: 317-701-4007
Newton F. Crenshaw  
*Eli Lilly and Company*

**Vice President, Lilly Oncology, U.S. and Canada**  
*Indianapolis, Indiana*

Newton “Newt” F. Crenshaw became vice president of the oncology business unit with responsibilities for commercial operations, business development and payer/advocacy relations in July 2011. He previously served as President of Lilly Japan from 2003 to 2008 and corporate vice president of global payer & corporate affairs from 2009 to 2011.

He received a Bachelor of Arts degree with honors in economics from DePauw University in 1985, where he was a management fellow in the university’s Center for Management and Entrepreneurship.

Crenshaw joined the company in 1985 as a sales representative in Charlottesville, Virginia and held various marketing and sales management roles during his first decade with the company.

Crenshaw led Lilly USA’s business-to-business organization in 1997 and was promoted to vice president, U.S. sales and marketing in 1998. He was named vice president of e.Lilly, formed in July 2000, to accelerate the use of new business models through the use of digital technologies, as well as the initiation of Lilly’s first venture investment fund. From 2002 to 2003, he served as vice president of communications and public affairs where he revitalized Lilly’s corporate branding effort.

Crenshaw serves on the board of trustees of DePauw University and chairs the local committee for Young Life in Zionsville. He has served on Young Life’s National Board of Trustees, was the founding board chair for Twelve Stones Ministries and chaired PhRMA’s executive committee for two years while in Japan.

**CONTACT INFORMATION**

Kelley Murphy  
Email: murphy_kelley@lilly.com  
Phone: 317-701-4007
Dr. Martin is vice president of clinical development operations, diabetes at Eli Lilly and Company and has responsibility for oversight of data science and solutions and global clinical operations, with focus on execution of the global diabetes Phase 3-4 portfolio. After joining Lilly in 2005, she served as U.S. affiliate medical director for the insulins/devices program. From 2010 to 2014, she was the global senior medical director responsible for the dulaglutide development program and regulatory submission, approved for market as Trulicity in the U.S. and EU in 2014. She has been extensively involved in Phase 3-4 clinical trial research and regulatory submissions, and has coauthored multiple publications in peer reviewed journals.

Dr. Martin attended the University of Mississippi Medical School. She completed her internal medicine residency at the University of North Carolina at Chapel Hill. After participating in a clinical pharmacology internship program in the Research Triangle, she initially returned to Mississippi to practice internal medicine in a multi-specialty clinic for several years. She subsequently continued her training with completion of an endocrinology and metabolism fellowship at Ochsner Clinic in New Orleans, Louisiana. For 15 years prior to entering the pharmaceutical industry, she was a private practice clinical endocrinologist in Mississippi, medical director of the North Mississippi Diabetes Treatment Center and served as an executive board member and chair of the medical staff for North Mississippi Health Services, the largest rural hospital system in the United States.
Dave Ricks was named senior vice president and president of Lilly Bio-Medicines in January 2012, and is a member of the company’s executive committee.

As president of Lilly Bio-Medicines, Ricks leads Bio-Medicines commercialization efforts for marketed medicines in more than 20 countries, along with half of Lilly’s late-stage drug development pipeline (Alzheimer’s disease, immunology and chronic pain). A 20-year Lilly veteran, Ricks previously led three of Lilly’s most important affiliates: the U.S., China, and Canada. He served as president of Lilly USA, the company’s largest affiliate, from 2009 to 2011.

Ricks earned a bachelor’s degree in industrial management from Purdue University in 1990, and an MBA from Indiana University in 1996. He has also worked for Hewlett Packard Corporation and IBM.

Active in trade issues between the United States and European Union, Ricks has served as the U.S. co-chair of the Trans-Atlantic Business Dialogue, and Chairman of the International Board Sponsored Committee of EFPIA (the European Federation of Pharmaceutical Industries and Associations). He also serves as chair of the Riley Children’s Foundation Board of Governors and is the 2015-16 Campaign Chair for United Way of Central Indiana. Ricks also sits on the Purdue Weldon School of Biomedical Engineering Advisory Board.

In his time away from work, he enjoys backpacking, jogging and spending time with his family. Ricks and his wife, Christina, have three children.

CONTACT INFORMATION
Kelley Murphy
Email: murphy_kelley@lilly.com
Phone: 317-701-4007
Michael J. Ruggiero
EMD Serono, Inc.

Vice President, U.S. Government Affairs and Policy
Washington, D.C.

Michael J. Ruggiero is a seasoned executive in the biopharmaceutical industry with a broad range of experience in policy, advocacy and government relations. He currently is vice president, U.S. government affairs and policy for EMD Serono, the U.S.-based biopharmaceuticals division of Merck KGaA, Darmstadt, Germany. He leads the function responsible for advising the company on the impact of U.S. policy on business strategy, and shaping the external policy environment to accomplish the company’s business objectives. Mr. Ruggiero sits on the U.S. country leadership team and the global government affairs and policy leadership team.

Before joining EMD Serono, Mr. Ruggiero was vice president, government strategy for Astellas Pharma US, Inc., where he led the function responsible for developing policy strategies to accomplish the company’s business objectives; designed and led the first Astellas federal policy and government affairs function; and led cross-functional/regional initiatives to address government policy at a global level.

Mr. Ruggiero previously practiced law in Washington, D.C. at the law firms of Arnold & Porter LLP and King & Spalding LLP, where he counseled and advocated on behalf of health care industry clients on a range of matters relating to product reimbursement and regulation.

Mr. Ruggiero is a former vice chair of the American Health Lawyers Association Life Sciences Practice Group, serves as adjunct faculty at the American University Washington College of Law and is immediate past chairman of the board of directors of the National Kidney Foundation Serving the National Capital Area. He earned a J.D. *cum laude* from the Georgetown University Law Center and a B.A. in economics from Syracuse University. Prior to attending law school, Mr. Ruggiero worked for the American Apparel Manufacturers Association and the American Textile Manufacturers Institute.

**CONTACT INFORMATION**

Michael J. Ruggiero
Email: michael.ruggiero@emdgroup.com
Phone: 202-802-8127
Jack Bailey
GlaxoSmithKline plc
President, U.S. Pharmaceuticals
Research Triangle Park, North Carolina

As president, U.S. Pharmaceuticals, Jack Bailey leads GlaxoSmithKline’s (GSK) pharmaceuticals business in the United States and Puerto Rico. Having joined GSK in 2009, Jack previously served as senior vice president, overseeing policy, payers and vaccines with responsibility for government affairs, managed markets, the U.S. vaccines business unit and Puerto Rico operations.

Jack has successfully guided GSK through a rapidly changing U.S. health care environment, including the implementation of the Affordable Care Act, a competitive marketplace and the evolution of a value-based health care system – all with a focus on ensuring continued patient access to GSK’s medicines and vaccines.

Prior to GSK, Jack had a successful 18-year career with Eli Lilly, where he served in a variety of commercial leadership roles, including senior vice president, account-based markets division; general manager, Eli Lilly South Africa; and area director for the Sub-Saharan region.

Jack is based in Research Triangle Park, North Carolina, where he is actively involved in the community and currently serves on the board of directors for the North Carolina Biotechnology Center, the North Carolina Healthcare Quality Alliance and the North Carolina Chamber of Commerce.

Jack holds an MBA from the University of North Carolina Kenan Flagler School of Business. Jack and his wife, Robin, reside in Raleigh, North Carolina, with their two children, Emily and John.

CONTACT INFORMATION
Jenni Ligday
Email: jenni.r.ligday@gsk.com
Phone: 202-715-1049
Tanisha Carino, Ph.D.
GlaxoSmithKline plc

Vice President, U.S. Public Policy
Washington, D.C.

Tanisha Carino, Ph.D., serves as vice president, U.S. public policy at GlaxoSmithKline, which is committed to helping people do more, feel better and live longer. In her role, Dr. Carino promotes public policies in the best interest of patients and the public’s health.

She joined the company from Avalere Health, a strategic health care advisory company, where she oversaw advisory and research services for the nation’s leading life sciences companies as executive vice president.

Dr. Carino brings over 15 years of experience in consulting, management, health policy and strategy development across government, industry and academia. She is a recognized thought leader in the evolving U.S. regulatory environment, market access and commercial trends, as well as health technology and evidence-based medicine.

Dr. Carino has a Ph.D. in health policy from Johns Hopkins University and is a Fulbright scholar. She serves as an associate faculty member in the Johns Hopkins Bloomberg School of Public Health and is a board member of Bread for the City in Washington, District of Columbia.
Caroline De Marco is the vice president for regional accounts at GlaxoSmithKline (GSK), a position she has held since 2010. In this role, she is responsible for ensuring patient access and reimbursement coverage for GSK’s pharmaceuticals, vaccines and specialty medicines among regional payers and integrated health system customers, including Kaiser.

Caroline has over 25 years of experience in the pharmaceutical industry at GSK, serving in a number of positions including vice president, national GPO, Kaiser and federal health systems and regional vice president, northeast institutional sales. During her tenure, she has also held several marketing roles where she successfully launched new products, managed the strategic planning process and developed educational partnerships with non-traditional customers and health educators, including Oprah Winfrey’s O magazine.

Caroline has received a number of leadership accolades for her contributions to GSK and the pharmaceutical industry. She was selected by GSK to be featured on NBC 10’s Moms on the Move in 2005, named a 2004 “Rising Star” by the Healthcare Businesswomen’s Association and selected by GSK and the Olympic Committee to be a torchbearer for the Philadelphia 2002 Winter Olympic Games torch relay.

Caroline is based in Philadelphia, Pennsylvania, and is active in the community, serving as the president of The Penn Towne Chapter of The LINKs Inc.; a member of Alpha Kappa Alpha Sorority, Inc., and Jack & Jill of America, The Philadelphia Chapter; and serves on the board of the trustees for The Haverford School and AIM Academy. She graduated with honors from Howard University with a Bachelor of Business Administration in finance. She resides in Philadelphia with her husband, Jason, and their two sons, Carson and Noble.

**CONTACT INFORMATION**

Jenni Ligday
Email: jenni.r.ligday@gsk.com
Phone: 202-715-1049
Jamey Millar is senior vice president, managed markets and government affairs for GlaxoSmithKline’s (GSK) U.S. Pharmaceuticals. In this capacity, Jamey leads all U.S. payer functions, as well as government relations and public policy. Jamey continues to serve as a member of the corporate leadership team, as he did in his prior role as vice president and head of the U.S. oncology business.

Jamey has extensive sales and marketing experience working with providers, hospitals, health systems and public and private payers across therapeutic areas, including respiratory, GSK’s largest therapeutic area. He has held a number of leadership positions since joining GSK in 2001, including four years in managed markets as vice president, strategic pricing, contracting and payer marketing. Prior to joining GSK, Jamey spent 11 years with Procter & Gamble, where he held a variety of positions, including country manager for the United Kingdom, the Netherlands and Ireland.

Jenni Ligday
Email: jenni.r.ligday@gsk.com
Phone: 202-715-1049
Jeffrey D. Kent, M.D., FACP
Horizon Pharma

Senior Vice President, Medical Affairs and Clinical Outcomes
Deerfield, Illinois

Jeffrey D. Kent, M.D., FACP, is senior vice president, medical affairs and clinical outcomes for Horizon Pharma, a role he assumed in May 2012.

Previously, Dr. Kent served as executive director, medical affairs for Astellas Pharmaceuticals, which he joined in 2011. Prior to that, in 2005, Dr. Kent became the global project head for medical affairs in immunology within Abbott Global Pharmaceutical Research and Development (Abbott). In this capacity, he had global medical affairs responsibility for HUMRIA across the rheumatology, dermatology and gastroenterology therapeutic areas. Dr. Kent began his industry career with Searle (now Pfizer), where he served in various capacities in research and development, including the global director for valdecoxib (Bextra) development.

Additionally, Dr. Kent served as associate medical director for the Evanston Hospital clinical pharmacology unit, a Phase I clinical trials facility and gained experience with first-in-man and ADME studies. Prior to that experience, he served as a full-time faculty member for several years in the department of internal medicine and the division of digestive diseases at Rush Medical College and Rush Presbyterian St. Luke’s Hospital. While at Rush, Dr. Kent was heavily involved with clinical practice, educating medical students, residents and fellows, and developed extensive experience with Phase II-IV clinical trials.

Dr. Kent is a graduate of Franklin and Marshall College and the Jefferson Medical College in Philadelphia, where he received his M.D. degree. He completed a residency in internal medicine at Thomas Jefferson University Hospital and a fellowship in gastroenterology and hepatology at Rush Presbyterian St. Luke’s Hospital in Chicago.

CONTACT INFORMATION

Geoff Curtis
Email: gcurtis@horizonpharma.com
Phone: 224-383-3333
Jeffrey W. Sherman, M.D., FACP
Horizon Pharma

Chief Medical Officer and Executive Vice President
Deerfield, Illinois

Jeffrey (Jeff) W. Sherman, M.D., FACP, is chief medical officer and executive vice president at Horizon Pharma based in Deerfield, Illinois. Jeff has more than 25 years of experience in the pharmaceutical industry.

Before joining Horizon Pharma, Jeff was chief medical officer and senior vice president of research and development at IDM Pharma. He also served previously as vice president of clinical science at Takeda Global Research and Development and chief medical officer and executive vice president at NeoPharm.

In addition, Jeff held various positions at Searle/Pharmacia, including director, senior director and executive director of clinical research for a variety of therapeutic areas, including infectious diseases, women’s health, sleep, central nervous system and oncology. He also served as head of oncology global medical operations. Prior to Searle/Pharmacia, Jeff worked at Bristol-Myers Squibb in clinical pharmacology and clinical research.

Jeff received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internship and residency in internal medicine at Northwestern University, where he also served as chief medical resident. Additionally, he completed fellowship training at the University of California-San Francisco (UCSF) and was a research associate at the Howard Hughes Medical Institute at UCSF. Jeff is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and a member of a number of professional societies, as well as a diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine.

Jeff is a past president of the Drug Information Association (DIA) and a former member of the board of directors. He also was chairperson of the DIA Annual Meeting, received an Outstanding Service Award, is an inaugural fellow and serves as the DIA liaison to the FDA Clinical Trial Transformation Initiative steering committee. Jeff, in addition, serves on the board of advisors of the Center for Information and Study on Clinical Research Participation.

CONTACT INFORMATION
Geoff Curtis
Email: gcurtis@horizonpharma.com
Phone: 224-383-3333
Anastasia G. Daifotis, M.D., is the chief scientific officer, Janssen North America. Anastasia leads the Janssen Scientific Affairs Organization and the Janssen Medical and Scientific Affairs Council.

As the leader of Janssen scientific affairs, Anastasia sets the medical strategy for Janssen North America. She is responsible for accelerating the development of medical and scientific capabilities essential to differentiating in a value-based health care system, such as real world evidence and health care economics, for pharmacovigilance and for medical information, including our call center operations. She partners closely with our R&D and global medical affairs leadership on product development programs and plays an important medical role in licensing and acquisitions. As leader of the Medical and Scientific Affairs Council for Janssen North America, Anastasia is responsible for shaping the medical and scientific vision for the region internally and representing Janssen externally on advisory and policymaking bodies across the region.

Anastasia graduated from Princeton University with an undergraduate degree in biology and received her M.D. from Albany Medical College. She held clinical and research fellowships in endocrinology and a Howard Hughes fellowship at the Yale University School of Medicine and Yale-New Haven Hospital.

CONTACT INFORMATION
Meredith Sharp
Email: msharp7@its.jnj.com
Phone: 202-589-1048
Elizabeth “Liz” Fowler, Ph.D., J.D., is vice president of global health policy for Johnson & Johnson. Liz is responsible for driving compassionate public policy to expand access to high-quality, affordable health care worldwide while promoting the value of innovation to improve the standard of patient care.

Liz joined Johnson & Johnson in 2012 from the White House, where she served as special assistant to the President for health care and economic policy at the National Economic Council. During the health reform debate from 2009 to 2010, she was chief health counsel to former Senator Max Baucus (D-MT), then-chair of the Senate Finance Committee, where she played a critical role in developing the Senate version of the Affordable Care Act. In a previous stint with the Senate Finance Committee, Liz also played a key role in the 2003 Medicare Prescription Drug, Improvement and Modernization Act. Liz has more than 20 years of experience in health policy and health services research. She has served as vice president of public policy and external affairs for WellPoint, Inc., and as an attorney with the Washington law firm Hogan & Hartson (now Hogan Lovells). Liz also spent five years as a health services researcher with the Park Nicollet Medical Foundation in Minneapolis, Minnesota.

Liz has a B.A. from the University of Pennsylvania, a Ph.D. from the Johns Hopkins Bloomberg School of Public Health, where her research focused on risk adjustment, and a J.D. from the University of Minnesota. She is admitted to the bar in Maryland, the District of Columbia and the U.S. Supreme Court.

CONTACT INFORMATION

Meredith Sharp
Email: msharp7@its.jnj.com
Phone: 202-589-1048
Blasine Penkowski is the chief strategic customer officer at Janssen North America. She currently leads an integrated team responsible for relationships with insurance companies, pharmacy benefit managers, integrated delivery networks and corporatized providers – focused on innovative approaches and opportunities across customer sectors in today’s complex health care marketplace.

Blasine is a seasoned leader with a strong track record of success in the pharmaceutical industry. During her 25 years at AbbVie (formerly Abbott’s Pharmaceutical Division), she built businesses, held senior positions in a variety of disciplines and steered the way in shaping innovative approaches to addressing unmet medical needs. She served in positions of increasing responsibility in account management and managed care marketing before being named vice president/general manager, managed markets and trade. In her tenure as a vice president, she was responsible for businesses in neuroscience, endocrinology, virology, pain and asthma, and mature products, and she established and prepared for the launch of AbbVie into the oncology market. She also led enterprise-wide efforts to shape AbbVie’s approach to critical business challenges and opportunities, including real world evidence, and built AbbVie’s first global strategic marketing department.

Blasine was named one of Healthcare Businesswomen’s Association’s rising stars of 2004 and held multiple board positions for the Chicago Chapter.

Blasine holds a Master of Business Administration from Indiana University Kelley School of Business and a Bachelor of Science in Chemical Engineering from Purdue University.
Matthew Harbaugh is the senior vice president and chief financial officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for the finance, information technology and global medical imaging commercial functions.

Mr. Harbaugh has more than 20 years of experience in controllership, corporate finance, business development and licensing, financial planning and analysis and investor relations.

Previously, Mr. Harbaugh served as the chief financial officer and interim president of the pharmaceuticals division of Covidien. He has worked as a lead finance executive at Cerberus Capital Management, L.P., a New York-based private equity firm. He also spent 10 years at Monsanto, where he held several positions, including corporate finance director, investor relations manager and finance director/chief financial officer for the company’s southern Argentine/Chilean and Canadian operations.

Mr. Harbaugh holds a bachelor’s degree in finance from Saint Louis University in St. Louis, Missouri and an MBA from Northwestern University in Evanston, Illinois.
Hugh O’Neill is the senior vice president and president of autoimmune and rare diseases (ARD) at Mallinckrodt Pharmaceuticals. He has executive responsibility for this business within the company’s specialty brands segment, as well as for the specialty generics segment, which includes specialty generics and active pharmaceutical ingredients. He directly manages all commercialization efforts and broad market access activities for these businesses.

Mr. O’Neill has more than 20 years of experience in new product planning and execution, business development, strategic planning, marketing, general management, finance and market access in the pharmaceutical industry.

Before joining Mallinckrodt, Mr. O’Neill held various commercial leadership positions at Sanofi, including vice president of commercial excellence, general manager, president of Sanofi Canada and vice president of market access and business development. He has also worked at Pharmacia, Novartis and Sandoz, crafting commercial strategies and operational plans across all facets of various organizations — including commercial coordination within research and development, new product launches, field force leadership, strategic marketing, business development and market access.

Mr. O’Neill holds a bachelor’s degree in finance from Montclair State University in Montclair, New Jersey, and an MBA in marketing from Seton Hall University in South Orange, New Jersey.

**Hugh O’Neill**

Mallinckrodt

Senior Vice President and President, Autoimmune and Rare Diseases

*St. Louis, Missouri*

---

**CONTACT INFORMATION**

Hugh O’Neill

Email: hugh.o’neill@mallinckrodt.com

Phone: 314-654-5280
Steven Romano, M.D.
Mallinckrodt
Senior Vice President and Chief Scientific Officer
St. Louis, Missouri

Dr. Steven Romano is the senior vice president and chief science officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions. Dr. Romano is a board-certified psychiatrist with more than 20 years of experience in the pharmaceutical industry.

Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating in his most recent position as senior vice president, head, global medicines development, global innovative pharmaceuticals business. Prior to joining Pfizer, he spent four years at Eli Lilly.

After receiving his A.B. in biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia, Dr. Romano completed his residency and fellowship at New York Hospital-Cornell Medical Center, continuing on the faculty of the medical school for six additional years.

CONTACT INFORMATION
Steven Romano
Email: steve.romano@mallinckrodt.com
Phone: 314-654-3704
Patrick Davish
Merck & Co., Inc.

Associate Vice President,
Global Market Access - Global Pricing
Upper Gwynedd, Pennsylvania

Patrick Davish is currently the associate vice president for global market access with responsibility for global pricing. In that capacity, Patrick leads the organization responsible for the pricing and reimbursement strategies for all of Merck's products globally, which includes U.S. pricing and reimbursement operations. Patrick also serves as executive vice president of Merck's Patient Assistance Foundation.

Patrick joined Merck in 1993 and has held positions of increasing responsibility within the Merck legal department, Merck's office of federal policy and legislation, public affairs and policy and global market access. Before joining Merck, Patrick worked as an associate at the Ballard Spahr and Dilworth Paxson law firms in Philadelphia. He practiced litigation law in complex commercial matters and represented numerous Fortune 500 companies.

Patrick is a graduate of the University of Pennsylvania, magna cum laude, and the Harvard Law School. He lives in Bucks County, Pennsylvania, with his wife, Anne, and son, Max.

CONTACT INFORMATION
Patrick Davish
Email: patrick_davish@merck.com
Phone: 267-305-0225
Patrick Magri currently serves as senior vice president of Merck’s, hospital and specialty business unit in the United States. In this capacity, Mr. Magri has P&L responsibility and oversees commercial activities related to strategy development and execution for all products in the hospital/specialty portfolio, across multiple therapeutic areas.

Mr. Magri joined Merck in 1990 and has held positions of increasing responsibility across a number of disciplines. During his tenure he has served as market research manager, product manager, sales district manager, director of the bone measurement institute and senior director of marketing. Mr. Magri also held leadership positions with Merck/Schering-Plough Pharmaceuticals and Merck’s Hospital and Specialty Executive Committee.

In 2004, Mr. Magri was appointed vice president, marketing, leading the osteoporosis franchise, subsequently taking on responsibilities for the U.S. Diabetes franchise where he was responsible for the market introductions of both JANUVIA and JANUMET. Mr. Magri has also served as business unit leader for Merck’s cardiovascular/metabolic franchises in the United States. In 2009, Mr. Magri was appointed senior vice president and general manager for the cardiovascular global pharmaceutical franchise where he was responsible for the direction of commercial strategies and late stage development of the integrated cardiovascular portfolios of Merck and Schering Plough.

Mr. Magri received his Bachelor of Science degree in biology from the University of Notre Dame and his Master of Business Administration from Rutgers University. He currently serves as chairman of the board of directors for the National Pharmaceutical Council and as a member of the Economic Advisory Council of the Federal Reserve Bank of Philadelphia.

CONTACT INFORMATION
Patrick Magri
Email: patrick_magri@merck.com
Phone: 267-305-9920
William Hinshaw
Novartis Pharmaceuticals Corporation

Executive Vice President, U.S. Oncology
East Hanover, New Jersey

Bill Hinshaw is executive vice president and head of the U.S. In this role he is responsible for all commercial and medical operations covering the United States.

Bill has held a number of increasingly senior roles in Novartis with his most recent being, head of the Northern and Central Europe Region for oncology where he was responsible for leading all functions across 33 countries. Prior to that role, Bill was the head of group emerging markets, which included all divisions of Novartis Corporation in 50 countries worldwide. He was also the global head of infectious diseases, transplant and immunology business franchise.

Before joining Novartis, Bill worked at the former Schering Plough Corporation where he held a series of commercial roles of increasing responsibility, including the head of U.S. oncology.

CONTACT INFORMATION
William Hinshaw
Email: william.hinshaw@novartis.com
Phone: 862-778-3415
For Christi Shaw, “more moments for more memories” isn’t just a mantra – it’s a personal and professional mission. In her multi-faceted role as U.S. country head, president of Novartis Corporation and president of Novartis Pharmaceuticals Corporation, Christi leads through the lens of innovation, integrity and inclusion.

As U.S. country head, Christi has oversight of 23,500 associates across Novartis U.S. group companies in three divisions - Pharmaceuticals, Alcon, and Sandoz - as well as the Novartis Institutes for BioMedical Research. She’s also responsible for government relations, external affairs and Novartis’ corporate reputation in the U.S.

As president of Novartis Pharmaceuticals Corporation, she leads the pharma business in the U.S., including day-to-day operations of the U.S. general medicines business, comprising cardiovascular and respiratory, dermatology and immunology and neuroscience. In all of her roles, she maintains an unwavering commitment to addressing the evolving needs of patients in collaboration with health care professionals, advocacy groups, payers and policy makers.

Joining Novartis in July 2010 as head of North America oncology, Christi oversaw all operations of that business including medical, commercial and staff functions for the U.S. and Canada. Her oncology legacy includes championing the groundbreaking “Signature” program, which is revolutionizing clinical trial recruitment by bringing the protocol to the patient versus the patient to the protocol. As a result, treatments are now getting to cancer patients in three to five weeks on average, compared to six months.

Christi’s more than 25 years of experience includes leadership positions at Johnson & Johnson and Eli Lilly & Company. Currently, she serves on the board of the Biotechnology Industry Organization (BIO), the Healthcare Leadership Council and the Young Women’s Leadership Network, which is committed to empowering at-risk young women through education.

CONTACT INFORMATION

Christi Shaw
Email: christi.shaw@novartis.com
Phone: 862-778-5626
Bob Spurr is U.S. country head and vice president, patient access and health policy for U.S. general medicines at Novartis Pharmaceutical Corporation. He is responsible for strategically aligning resources to strengthen the value the company brings to leading customers, including pharmacy benefit managers, insurers, Medicare, Medicaid, Veterans’ Affairs, Department of Defense, senior care, chain pharmacies, wholesalers, employers, patients and physicians. Bob is also responsible for leading U.S. health policy, state government affairs, the patient & specialty services team, as well as sales, marketing and overall strategic development of the company’s established medicines business. He is a member of the U.S. Country Executive Committee, the U.S. General Medicines Executive Committee and the U.S. Pharmaceutical Executive Committee.

Bob, who has more than 25 years of commercial pharmaceutical experience in sales, marketing and managed markets, most recently held the position of head of Novartis U.S. oncology market access. He began his career at Sandoz, serving in several sales and managed markets roles over 10 years, before moving to Aventis where he led a number of marketing and managed care teams. Bob later joined Ortho-McNeil where he was vice president of sales and marketing for its institutional franchise. Before joining Novartis U.S. oncology in 2012, Bob held sales and marking executive leadership positions at Lantheus Medical Imaging and Repligen Corporation.

Throughout his career, Bob has been an action-oriented leader, committed to ensuring that appropriate patients have access to the medications they need. As head of U.S. oncology market access, he led overall strategic planning and tactical execution for all oncology managed markets/market access activities across the portfolio. Bob holds a Bachelor of Science degree from Keene State College in New Hampshire and earned an Executive MBA from Rutgers, The State University of New Jersey.

CONTACT INFORMATION
Robert Spurr
Email: robert.spurr@novartis.com
Phone: 862-778-1376
Todd Hobbs, M.D.

Novo Nordisk, Inc.

Vice President, Chief Medical Officer, North America
Plainsboro, New Jersey

Todd Hobbs, M.D., is vice president and chief medical officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, health care system and health care professionals.

Dr. Hobbs provides overall medical guidance to Novo Nordisk’s diabetes- and obesity-related projects. He provides input into the clinical development and life-cycle management strategies for diabetes and obesity, as well as medical input into the R&D pipeline. He is involved with the optimization of relationships with top key opinion leaders and medical societies, and provides guidance to and participates in consultant advisory boards and key patient and professional associations and top thought leaders in diabetes.

Dr. Hobbs began his career at Novo Nordisk in 2004 as a field medical scientific director, then moving to the position of senior medical director, diabetes, in 2010. He led the medical affairs activities for all of Novo Nordisk’s current insulin products and devices, as well as supporting future insulin products through strategic and tactical activities.

In 2016, he will begin a 3-year term on the board for the American Medical Group Foundation (AMGF), the research foundation arm of the American Medical Group Association (AMGA).

Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages and served as chairman of the medicine department for a large regional medical center in Kentucky. During this 10-year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.

CONTACT INFORMATION

Todd Hobbs, M.D.
Email: tddh@novonordisk.com
Phone: 609-786-4167
Curt G. Oltmans
Novo Nordisk, Inc.

Corporate Vice President and General Counsel
Plainsboro, New Jersey

Curt G. Oltmans is corporate vice president & general counsel for Novo Nordisk Inc., North America. He is responsible for strategy and initiatives in the areas of law, quality, intellectual property, U.S. corporate giving & social impact, government affairs and public affairs for the company’s substantial business in North America. He is a member of the company’s North American executive team and serves on various internal and global steering groups and committees. He joined Novo Nordisk Inc. in 2005.

In addition to his responsibilities managing the legal, patents, quality & public affairs department, he is leading Novo Nordisk’s Native American Health Initiative. Currently, the project is working with the Rosebud Sioux Tribe in Rosebud, South Dakota. The project includes diabetes education, donation of a Wellness Center and mobile medical unit.

Curt graduated from the University of Nebraska College of Law, with high distinction, in 1988 and from the University of Nebraska with a Bachelor of Arts in political science in 1985. He is admitted to practice law in Indiana and Missouri. He also maintains a limited law license in New Jersey.

Prior to joining Novo Nordisk he held various positions in the legal department of Eli Lilly and Company (1992-2005), including positions based in Europe and the United States. While in these roles, he visited more than fifty countries. He has also worked as an associate at Shook, Hardy & Bacon in Kansas City, Missouri (1989-1992), as well as a visiting associate at Cameron McKenna (1988-1989) in London, U.K.

He is a board of trustees member for the Boys & Girls Club of Trenton & Mercer County (NJ).

CONTACT INFORMATION

Curt Oltmans
Email: cuot@novonordisk.com
Phone: 609-987-4875
Sean Phillips is currently the vice president of managed markets strategy, in diabetes & obesity marketing at Novo Nordisk Inc in Plainsboro, New Jersey.

In this position he is responsible for managed care, government and institutional strategic contract strategy and marketing.

Sean joined Novo Nordisk in March of 2001 as the senior director, managed care and government. Over the past 20 years he has held various leadership positions in sales, managed markets and marketing in the pharmaceutical industry.

Sean is a licensed Pharmacist in the state of Illinois and a U.S. Army veteran.

CONTACT INFORMATION

Sean Phillips
Email: seap@novonordisk.com
Phone: 609-786-4264
Michael A. Narachi has served as our president and chief executive officer and a member of our board of directors since March 2009. Previously, Mr. Narachi served as chairman, chief executive officer and president of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company.

In 2004, Mr. Narachi retired as an officer and vice president of Amgen Inc., a leading therapeutics company, where he served as general manager of Amgen’s anemia business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: product development team leader for NEUPOGEN® Director of Clinical Operations in Thousand Oaks, California and Cambridge, U.K.; vice president of development and representative director for Amgen Japan; head of corporate strategic planning; chief operations officer of Amgen BioPharma; and vice president, licensing and business development. He currently serves on the board of directors of Celladon Corporation and Ultragenyx Pharmaceutical, Inc., both are publicly traded biotechnology companies.

Mr. Narachi received a B.S. in biology and an M.A. degree in biology and genetics from the University of California at Davis. He received an MBA from the Anderson Graduate School of Management at University of California, Los Angeles. Mr. Narachi also currently serves as a member of the board of directors of PhRMA, the Pharmaceutical Research and Manufacturers of America; and BIO, the Biotechnology Industry Organization.

CONTACT INFORMATION

Michael A. Narachi
Email: mnarachi@orexigen.com
Phone: 858-875-8601
John Bardi is vice president, government affairs and business development lead for Otsuka’s digital medicine platform at Otsuka America Pharmaceutical, Inc. In his role at Otsuka, John oversees and directs all government affairs efforts at the federal and state level along with stakeholder engagement with key consumer advocacy organizations focused primarily in the areas of mental health, oncology, and Alzheimer’s disease. As business development lead for Otsuka’s emerging digital medicine platform, John will direct stakeholder engagement with U.S. payers and policy makers.

Prior to entering the pharmaceutical industry, John served as vice president, clinical and professional services, at The Children’s Hospital of Philadelphia.

John received a B.A. degree from West Chester University and a Master of Health Services Administration degree from the George Washington University.

Before joining Otsuka, John worked as vice president, U.S. managed markets and senior director, marketing for ABILIFY® (aripiprazole) at Bristol-Myers Squibb. Earlier, he worked at GlaxoSmithKline as vice president, long term care channel accounts and director of national accounts, institutional sales.

CONTACT INFORMATION

John Bardi
Email: john.bardi@otsuka-us.com
Phone: 240-683-3153
Rob Laverty
Otsuka America Pharmaceutical, Inc.

Vice President, Market Access
Princeton, New Jersey

Rob Laverty is vice president of market access at Otsuka America Pharmaceutical, Inc. (OAPI). He is a member of the brand development & commercialization and pharmaceutical operating committees and the joint executive team. Rob previously served the company as senior director of market access. He continues to be responsible for payer and trade strategy and interactions, pricing strategy, contracting, market access operations and development of early market access strategy.

Before joining Otsuka in 2012, Rob spent 18 years at Bristol-Myers Squibb, where he was most recently the executive director of global market access. Rob’s team built worldwide market access strategies and developed value stories for the neuroscience, cardiovascular and metabolic pipelines.

Rob received a B.S. degree in management science from Kean University and an MBA in finance from Fairleigh Dickinson University – Madison Campus in New Jersey.

CONTACT INFORMATION
Rob Laverty
Email: rob.laverty@otsuka-us.com
Phone: 609-853-2214
Bob Oliver
Otsuka America Pharmaceutical, Inc.
President & Chief Operating Officer
Princeton, New Jersey

Bob Oliver is a 25 year veteran of the pharmaceutical industry. He is currently the president and chief operating officer for Otsuka America Inc. where he manages a diverse portfolio of marketed and pipeline products. During the span of his career Bob has held general management and executive roles including vice president and global business manager for the oncology franchise at Wyeth where he was also senior vice president U.S. operations and the Caribbean.

He began his career in the pharmaceutical industry with Johnson & Johnson where he held positions of increasing responsibility in both domestic and global business operations. He has also had responsibility for multiple blockbuster brands and sizable organizations over the course of his career.

Bob has led multiple product launches in gastrointestinal, central nervous system, oncology and other therapeutic categories. In addition to his responsibility overseeing the U.S. commercial organization for Otsuka America, he is also responsible for the Canadian affiliate Otsuka Canada Pharmaceutical, Inc., or OCPI.

During his tenure with Johnson & Johnson, Wyeth and OAPI, Bob has honed his skills in managing partnerships and alliances. He promotes open innovation and is a proponent of the mantra “all for creativity” which was coined at the parent organization of OAPI. As a leader of transformational change, Bob is focused on both internal business operations and cultivating external business relationships.

Bob holds a BA from Rutgers University and an MBA from St. Joseph’s University.

CONTACT INFORMATION
Bob Oliver
Email: bob.oliver@otsuka-us.com
Phone: 609-524-6830
Kirsten Axelsen
Pfizer Inc.
Vice President, Global Policy
New York, New York

Kirsten Axelsen is vice president global policy at Pfizer. She leads a team that analyses how changes in health policy affect Pfizer, health care providers and their patients and offers strategic guidance based on the analysis. Kirsten began her career at Pfizer in 2000. Kirsten also serves on Pfizer’s Real World Data Steering Committee.

Kirsten earned a B.S. in economics, from the University of Puget Sound and an M.S. in economics from the University of Texas, Austin. In 2006, Kirsten was awarded a Global Health Fellowship to work with the International Trachoma Initiative in Ethiopia.

CONTACT INFORMATION
Kirsten Axelsen
Email: kirsten.axelsen@pfizer.com
Phone: 212-733-8321
Geno Germano

Pfizer Inc.

Group President, Global Innovative Pharma Business

New York, New York

Geno Germano is group president of Pfizer’s global innovative pharma business, the company’s operating unit focused on development, registration and commercialization of novel, value creating medicines that significantly improve patients’ lives. In this role, Germano leads a growing global business with market-leading medicines and a robust pipeline in several therapeutic areas including inflammation, cardiovascular and metabolic disease, neuroscience and pain and rare diseases. Additionally, Germano is co-chair of the portfolio strategy and investment committee which focuses on maximizing the return on research and development investment across the Pfizer Inc. portfolio. Germano is a member of Pfizer’s executive leadership team.

Previously, Germano served as president and general manager of Pfizer’s specialty care and oncology business units.

With more than 25 years of international experience in the pharmaceutical industry, Germano has held many positions including executive vice president and general manager for Wyeth Global Vaccines; managing director, Wyeth Australia and New Zealand and executive vice president and general manager of the pharmaceutical business unit. He led numerous product launches in primary and specialty care therapeutic areas. Germano also held various commercial development and strategy positions at Johnson & Johnson companies. Prior to joining the pharmaceutical industry, Germano was a pharmacist, where he first developed his zeal for science that makes a difference for patients.

Germano serves as a member of the board of the Biotechnology Industry Organization (BIO); on the advisory board of the Healthcare Businesswomen’s Association and as a trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in pharmacy.

CONTACT INFORMATION

Geno Germano
Email: geno.germano@pfizer.com
Phone: 212-733-3849
Justin McCarthy, J.D.
Pfizer Inc.

Senior Vice President,
Global Policy and International Affairs
New York, New York

Mr. McCarthy is a senior vice president at Pfizer Inc. and in January 2014 established the global policy and international public affairs function. In this role, Mr. McCarthy is responsible for defining Pfizer’s global policy positions and driving the advocacy agenda internationally. He leads Pfizer’s engagement in international trade and business associations, and serves on the boards of the Business Council for International Understanding and Acritas and on the harmonization subcommittee of the Health and Human Services secretary’s Advisory Committee on Human Research Protections (SACHRP). He also serves as secretary to the Pfizer Board’s Science and Technology Committee. Most recently, Mr. McCarthy was the chief counsel for Pfizer’s worldwide research and development division. In that role, he coordinated all legal support, advised on regulatory, policy and bioethics matters and held responsibility for Pfizer’s global intellectual property activities.

He has extensive experience negotiating novel research collaborations with academia, governments and other biopharmaceutical companies.

Mr. McCarthy joined Pfizer in 1993 based at corporate headquarters in New York, where he provided regulatory law support for all Pfizer businesses. In 1998, he relocated to Brussels, where he provided legal support to Pfizer’s European operations. He returned to the U.S. in 2001 to support Pfizer’s expanded research and development operations after the merger with Warner-Lambert.

Prior to joining Pfizer in 1993, Mr. McCarthy was an associate in the Washington, D.C. law firm of Keller & Heckman, where he focused primarily on food and drug law.

He holds a B.S. in pharmacy from the University of Rhode Island and a J.D. from the Catholic University of America.

CONTACT INFORMATION

Justin McCarthy, J.D.
Email: justin.mccarthy@pfizer.com
Phone: 212-733-9837
Paul Chew, M.D.
Sanofi
Global Chief Medical Officer
Bridgewater, New Jersey, and Paris, France

Paul Chew is the senior vice president, group chief medical officer and head of the North America R&D hub for Sanofi. Between 2009 through 2012, Paul was the senior vice president, chief science officer, chief medical officer, Sanofi U.S. Between 2007 and 2009, Paul held the position of president, U.S. research & development and vice president, therapeutic department head, metabolism, diabetes and thrombosis, in which role he was responsible for Lovenox, Lantus and the therapeutic development portfolio. In addition, he is currently a member of external advisory board for the Gillings School of Public Health, University of North Carolina and a member of the Institute of Medicine Value & Science-Driven Healthcare Roundtable. Prior to Sanofi, Paul was vice president, global head of metabolism and diabetes at Aventis Pharmaceuticals (2001-2004).

Paul received his medical degree from The Johns Hopkins School of Medicine. He obtained his internal medicine training and cardiology fellowship at The Johns Hopkins Hospital.

CONTACT INFORMATION
Maria Escalante
Email: mara.escalante@sanofi.com
Phone: 908-981-2332
Suresh Kumar
Sanofi
Executive Vice President, External Affairs
Paris, France

Suresh Kumar has an economics degree from Delhi University and a masters in management from Bombay University. Suresh has more than 30 years of experience in the health care industry beginning in 1978 in India with Johnson and Johnson. At Warner Lambert from 1989 to 1999, he held increasingly senior roles in consumer health care in Canada, North America, Latin America and Asia. Mr. Kumar again joined Johnson & Johnson in 1999 as a member of the group operating committee and international vice president of the worldwide consumer pharmaceuticals business.

In 2006, Mr. Kumar joined the Clinton Foundation as special advisor focused on sub-Saharan Africa, where he created programs focused on enhancing lives through improved agricultural performance and food security.

In 2010, the United States Senate unanimously confirmed Mr. Kumar as assistant Secretary of Commerce and director general of the U.S. and Foreign Commercial Service where he spearheaded global trade for the Obama administration.

Since 2013, Mr. Kumar has served as a partner with Oliver Wyman leading the firm’s public sector practice and as part of the health and life sciences team.

He was appointed to his present position in June 2015.

Brandi Robinson
Email: brandi.robinson@sanofi.com
Phone: 908-981-5400
David Meeker, M.D.
Sanofi Genzyme

Executive Vice President and Head, Sanofi Genzyme
Cambridge, Massachusetts

David Meeker, M.D., is executive vice president and head of Sanofi Genzyme, the specialty care global business unit of Sanofi, which focuses on rare diseases, multiple sclerosis, oncology and immunology. As an executive vice president of Sanofi, he is a member of the executive committee.

Dr. Meeker joined Genzyme in 1994 as medical director to work on the cystic fibrosis gene therapy program. Subsequently, as vice president, medical affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to the merger with Sanofi in 2011, Dr. Meeker was chief operating officer, responsible for Genzyme’s commercial organization, overseeing its business units, country management organization and global market access functions. In October 2011, he was appointed president and chief executive officer of Genzyme, a Sanofi company.

Prior to joining Genzyme, Dr. Meeker was the director of the pulmonary critical care fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters.

Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

CONTACT INFORMATION
Bo Piela
Email: bo.piela@genzyme.com
Phone: 617-768-6579
Jez Moulding
Sanofi

U.S. Country Chair
North America Region Head, Diabetes & Cardiovascular Business Unit
Bridgewater, New Jersey

Jez Moulding is U.S. country chair and North America region head for the diabetes and cardiovascular business unit for Sanofi, a global diversified healthcare company. Jez oversees all commercial operations for the diabetes and cardiovascular business unit in the U.S. and Canada, including sales, marketing, value and access, integrated care and business support. As U.S. country chair, Jez leads a team comprised of the heads of Sanofi’s U.S. businesses and functions, including Sanofi Pasteur vaccines, Sanofi Genzyme specialty care, general medicines, Chattem consumer health and Merial, to drive strategic alignment across the U.S. and maximize Sanofi’s value for patients.

A distinguished and dedicated professional with more than 20 years of experience, Jez began his pharmaceutical career as a sales representative with Astra in the U.K. and moved onto positions of greater responsibility before joining Sanofi in 1998 as the U.K. cardiovascular marketing manager. At Sanofi, he held various leadership roles, including general manager positions in South Africa, Korea and Australia. He was head of the Japan and Pacific Region, Sanofi’s second largest market. Most recently, Jez was president of North America Pharmaceuticals, responsible for launching three new medicines in one year.

Jez holds an M.A. in politics, economic and social history from Edinburgh University.

CONTACT INFORMATION
Mary Kathryn Steel
Email: marykathryn.steel@sanofi.com
Phone: 908-981-3779
Gary J. Nabel, M.D., Ph.D.
Sanofi

Chief Scientific Officer, Global Research and Development
Paris, France, and Bethesda, Maryland

Gary J. Nabel, M.D., Ph.D. is chief scientific officer for global research and development at Sanofi. He also serves as a senior vice president and deputy to the president for global R&D and in this capacity chairs the Strategic Development and Scientific Advisory Council and ebola response coordination team for the company.

Dr. Nabel joined Sanofi in November 2012 from the National Institutes of Health (NIH), where he served as director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases since 1999. During his tenure at the NIH, Dr. Nabel provided overall direction and scientific leadership of the basic, clinical and translational research activities of the VRC and guided development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including ebola/marburg hemorrhagic fevers, influenza, chikungunya and other viruses.

Dr. Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his Ph.D. in 1980 and his M.D. two years later. He then served as a postdoctoral fellow in the laboratory of David Baltimore at the Massachusetts Institute of Technology’s Whitehead Institute. Before his appointment at the VRC, Dr. Nabel served as the Henry Sewall professor of internal medicine, professor of biochemistry and Howard Hughes Medical Institute investigator at the University of Michigan in Ann Arbor. In addition to his faculty positions, Dr. Nabel also served as the director of the Center for Gene Therapy and co-director of the Center for Molecular Medicine at the University of Michigan.

In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the Institute of Medicine of the National Academy of Sciences in 1998. Among his many other honors, Dr. Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service and is a fellow of the American Association of Physicians and the American Academy of Arts Sciences.
Elias Zerhouni, M.D., is the president, global research and development, and a member of the executive committee for Sanofi.

Dr. Zerhouni’s academic career was spent at the renowned Johns Hopkins University and Hospital where he was a professor of radiology and biomedical engineering and senior adviser for Johns Hopkins Medicine. He served as chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, vice dean for research and executive vice dean of the School of Medicine from 1996 to 2002 before his appointment as director of the National Institutes of Health (NIH) from 2002 to 2008. In that position, he oversaw the NIH’s 27 institutes and centers with more than 18,000 employees and a budget of $29.5 billion (2008).

In November 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys.

Dr. Zerhouni has founded or co-founded five start-up companies, authored more than 200 publications and holds eight patents and a number of prominent positions on several boards, including, most recently, the board of the Lasker Foundation. He is also a member of the U.S. National Academy of Medicine and U.S. National Academy of Engineering, received the prestigious Legion of Honor medal from the French National Order in 2008, was elected as a member of the French Academy of Medicine in 2010 and appointed as chair of innovation at the College de France in 2011.

CONTACT INFORMATION

Joanne Kennedy
Email: joanne.kennedy@sanofi.com
Phone: 514-235-4380
Richard “Rick” Ascroft  
_Takeda Pharmaceuticals USA, Inc._

_Vice President, Managed Markets and Government Affairs_  
_Deerfield, Illinois_

Rick Ascroft is responsible for managed markets and government and external affairs and serves as a member of the Takeda Pharmaceuticals U.S.A, Inc. executive team. Mr. Ascroft joined Takeda in November 2015. Prior to joining Takeda, Mr. Ascroft worked for Eli Lilly and Company for 22 years in a variety of clinical research, commercial, market access and corporate affairs roles. He has spent well over half of his career working in public affairs and managed markets roles in the U.S. and internationally, spending five years as the director of corporate affairs and market access for emerging markets and Japan, followed by three years as the senior director of corporate affairs and market access for the U.K. and Republic of Ireland and most recently four years as the senior director of corporate affairs, market access and pricing for Europe, Canada and Australia. Prior to these roles, Rick worked in U.S. federal public policy, clinical development and sales. Mr. Ascroft is the author of “The Impact of the Washington Legal Foundation Cases on Pharmaceutical Manufacturer Practices in the United States,” which was published in the _Indiana Law Review_ in 2000, and he led the industry effort to develop PhRMA’s Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results. In 2009, he was part of the industry team that provided input into the U.K. Government’s Office for Life Sciences Blueprint. In 2011, he presented to the British Parliament’s Science in Parliament Committee on _What is the Future for the Research-Led Pharmaceutical Industry_. The proceedings were captured in the autumn 2011 _Science in Parliament Journal_. In 2014, he co-authored, “The Case for HTA cooperation,” in _MedNous_.

Mr. Ascroft has a Bachelor of Science degree in pharmacy from Butler University in Indianapolis, Indiana and a law degree from the Indiana University School of Law, graduating _summa cum laude_.

**CONTACT INFORMATION**  
Richard Ascroft  
Email: richard.ascroft@takeda.com  
Phone: 224-554-1414
Ramona Sequeira is president of Takeda Pharmaceuticals U.S.A., Inc., and serves as a member of Takeda Pharmaceutical Company’s executive team. Ms. Sequeira joined Takeda in May 2015.

Ms. Sequeira is a seasoned commercial leader with experience leading, growing and transforming businesses. Prior to joining Takeda, she held various senior roles at Eli Lilly in Canada, Europe and the United States. During her career, she has led several successful product launches, created successful alliance relationships and managed affiliates and regions. She has a track record of creating and executing strategy and improving operational performance, workforce engagement, revenue growth and profitability. Ms. Sequeira is an active coach and mentor to many talented individuals and has a keen interest in leadership development. She has led numerous executive development programs and is a trained facilitator.

Ms. Sequeira is committed to helping shape a positive environment that rewards pharmaceutical innovation. During her time in the U.K., she was a member of the Association of the British Pharmaceutical Industry. Currently, she is a member of the PhRMA Board of Directors. PhRMA is the Pharmaceutical Research and Manufacturers of America, representing the country’s leading biopharmaceutical researchers and biotechnology companies. Additionally, Ms. Sequeira is a board member of the Healthcare Leadership Council, a coalition of executives from all disciplines within American health care. It is the exclusive forum for the nation’s health care leaders to jointly develop policies, plans and programs to achieve their vision of a 21st century system that makes affordable, high-quality care accessible to all Americans.

Ms. Sequeira received a B.S. with honors in molecular genetics and molecular biology from the University of Toronto and later received an MBA from McMaster University in Hamilton, Ontario. She lives with her husband of 20 years and their 2 teenage children near Takeda’s headquarters in Deerfield, Illinois.

CONTACT INFORMATION

Ramona Sequeira
Email: ramona.sequeira@takeda.com
Phone: 224-554-1788